0001594062-17-000003.txt : 20170117 0001594062-17-000003.hdr.sgml : 20170117 20170117171715 ACCESSION NUMBER: 0001594062-17-000003 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20161130 FILED AS OF DATE: 20170117 DATE AS OF CHANGE: 20170117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cell MedX Corp. CENTRAL INDEX KEY: 0001493712 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-MISCELLANEOUS RETAIL [5900] IRS NUMBER: 383939625 STATE OF INCORPORATION: NV FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54500 FILM NUMBER: 17531446 BUSINESS ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 BUSINESS PHONE: (844) 238-2692 MAIL ADDRESS: STREET 1: 123 W. NYE LN, SUITE 446 CITY: CARSON CITY STATE: NV ZIP: 89706 FORMER COMPANY: FORMER CONFORMED NAME: Sports Asylum, Inc. DATE OF NAME CHANGE: 20140324 FORMER COMPANY: FORMER CONFORMED NAME: Plandel Resources, Inc. DATE OF NAME CHANGE: 20100608 10-Q 1 form10q.htm 10-Q form10q.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
 
x                    Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended November 30, 2016
 
or
 
 
o                       Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
 
Commission File Number: 000-54500
 
Cell MedX Corp.
 (Exact name of registrant as specified in its charter)
 
Nevada
  
38-3939625
(State or other jurisdiction of
  
(I.R.S. Employer
incorporation or organization)
  
Identification No.)
 
123 W. Nye Ln, Suite 446
Carson City, NV
  
 
89706
(Address of principal executive offices)
  
(Zip code)
 
(844) 238-2692
 (Registrant’s telephone number, including area code)

2872 Sumter Valley Circle, Henderson, NV 89052
(Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  x Yes o No
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).  Yes    x    No    o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer  o
  
Accelerated filer  o
     
Non-accelerated filer  o
  
Smaller Reporting Company x
 
Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.) o Yes x No
 
The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of January 17, 2017 was 40,244,605.

 
 
 

CONTENTS
 

   
Page
 
PART I – FINANCIAL INFORMATION
  
     
Item 1.
Financial Statements
   3
     
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
   4
     
Item 3.
Quantitative and Qualitative Disclosure about Market Risk
   9
     
Item 4.
Controls and Procedures
   9
     
 
PART II – OTHER INFORMATION
  
     
Item 1.
Legal Proceedings
   10
     
Item 1A.
Risk Factors
   10
     
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
   12
     
Item 3.
Defaults Upon Senior Securities
   12
     
Item 4.
Mine Safety Disclosures
   12
     
Item 5.
Other Information
   12
     
Item 6.
Exhibits
   13
     
 
SIGNATURES
   15

--

 
2
 

PART I - FINANCIAL INFORMATION
 
Item 1. Financial Statements

The accompanying unaudited consolidated interim financial statements of Cell MedX Corp. as at November 30, 2016, have been prepared by the Company’s management in conformity with accounting principles generally accepted in the United States of America and in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles.  In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

Operating results for the three and six month periods ended November 30, 2016, are not necessarily indicative of the results that can be expected for the year ending May 31, 2017.

As used in this Quarterly Report, the terms “we,” “us,” “our,” “Cell MedX,” and the “Company” mean Cell MedX Corp. and its subsidiaries, Avyonce Cosmedics Inc., and Cell MedX (Canada) Corp., unless otherwise indicated. All dollar amounts in this Quarterly Report are expressed in U.S. dollars.

 
3
 

CELL MEDX CORP.

CONSOLIDATED BALANCE SHEETS
(EXPRESSED IN US DOLLARS)

 
   
November 30,
2016
    
May 31,
2016
  
ASSETS
  
(Unaudited)
        
             
Current assets
            
Cash
   $ 117,980     $ 27,561  
Inventory
     3,715       4,599  
Other current assets
     71,139       29,684  
Total current assets
     192,834       61,844  
                 
Equipment
     185,673       207,083  
Total assets
   $ 378,507     $ 268,927  
                 
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT
                
Accounts payable
   $ 396,836     $ 384,147  
Accrued liabilities
     8,412       37,966  
Due to related parties
     333,772       307,650  
Notes and advances payable
     130,128       951,716  
Unearned revenue
     11,172       -  
Total liabilities
     880,320       1,681,479  
                 
STOCKHOLDERS' DEFICIT
                
Common stock, $0.001 par value, 300,000,000 shares authorized;
                
40,244,605 and 31,000,000 shares issued and outstanding at November 30, 2016 and  May 31, 2016, respectively
     40,245       31,000  
Additional paid-in capital
     4,048,000       1,734,498  
Obligation to issue shares
     -       75,000  
Accumulated deficit
     (4,593,517 )     (3,254,597 )
Accumulated other comprehensive income
     3,459       1,547  
Total stockholders' deficit
     (501,813 )     (1,412,552 )
Total liabilities and stockholders’ deficit
   $ 378,507     $ 268,927  
                 
                 
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
  

 
F-1
 


CELL MEDX CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(EXPRESSED IN US DOLLARS)

 
   
Three Months Ended
November 30,
    
Six Months Ended
November 30,
  
   
2016
    
2015
    
2016
    
2015
  
                         
Revenue
                        
Sales
   $ 336     $ 3,767     $ 5,704     $ 5,649  
Cost of goods sold
     180       2,897       3,591       4,102  
Gross margin
     156       870       2,113       1,547  
                                 
Operating expenses
                                
Amortization
     18,510       2,587       36,521       6,500  
Consulting fees
     75,607       103,252       150,747       189,710  
General and administrative expenses
     51,239       52,721       95,463       120,683  
Research and development costs
     67,173       25,185       140,025       578,724  
Stock-based compensation
     29,306       290,281       78,203       606,866  
Total operating expenses
     241,835       474,026       500,959       1,502,483  
                                 
Other items
                                
Accretion expense
     (7,473 )     -       (13,730 )     -  
Gain on sale of equipment
     -       -       -       2,979  
Interest
     (5,596 )     (6,458 )     (20,991 )     (11,085 )
Loss on settlement of debt
     (805,353 )     -       (805,353 )     -  
Net loss
     (1,060,101 )     (479,614 )     (1,338,920 )     (1,509,042 )
                                 
Unrealized foreign exchange translation gain
     1,881       469       1,912       2,455  
Comprehensive loss
   $ (1,058,220 )   $ (479,145 )   $ (1,337,008 )   $ (1,506,587 )
Net loss per common share
                                
Basic and diluted
   $ (0.03 )   $ (0.02 )   $ (0.04 )   $ (0.05 )
                                 
Weighted average number of shares outstanding – basic and diluted
     36,014,128       31,000,000       33,493,364       31,000,000  
                                 
                                 
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
  

 
F-2
 
CELL MEDX CORP.

CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
(UNAUDITED)
(EXPRESSED IN US DOLLARS)



 
               
Obligation
    
 
     Accumulated Other
 
  
   
Common Stock
    
to Issue
    
Additional Paid-in
    
Deficit
     Comprehensive
 
  
   
Shares
    
Amount
    
Shares
    
Capital
    
Accumulated
     Income   
Total
  
                                           
Balance - May 31, 2015
     31,000,000     $ 31,000     $ 75,000     $ 324,629     $ (1,115,460 )   $ 765     $ (684,066 )
                                                         
Options issued for technology
     -       -       -       496,345       -       -       496,345  
Options issued for consulting fees
     -       -       -       20,364       -       -       20,364  
Stock-based compensation
     -       -       -       606,866       -       -       606,866  
Net loss for the six months ended November 30, 2015
     -       -       -       -       (1,509,042 )     -       (1,509,042 )
Translation to reporting currency
     -       -       -       -       -       2,455       2,455  
                                                         
Balance - November 30, 2015
     31,000,000       31,000       75,000       1,448,204       (2,624,502 )     3,220       (1,067,078 )
                                                         
Stock-based compensation
     -       -       -       261,294       -       -       261,294  
Warrants issued for term loan
     -       -       -       25,000       -       -       25,000  
Net loss for the six months ended May 31, 2016
     -       -       -       -       (630,095 )     -       (630,095 )
Translation to reporting currency
     -       -       -       -       -       (1,673 )     (1,673 )
                                                         
Balance - May 31, 2016
     31,000,000       31,000       75,000       1,734,498       (3,254,597 )     1,547       (1,412,552 )
                                                         
Stock-based compensation
     -       -       -       78,203       -       -       78,203  
Shares issued for cash
     2,383,333       2,383       -       355,117       -       -       357,500  
Shares issued for debt
     6,711,272       6,712       -       1,805,332       -       -       1,812,044  
Issuance of shares subscribed
     150,000       150       (75,000 )     74,850       -       -       -  
Net loss for the six months ended November 30, 2016
     -       -       -       -       (1,338,920 )     -       (1,338,920 )
Translation to reporting currency
     -       -       -       -       -       1,912       1,912  
                                                         
Balance - November 30, 2016
     40,244,605     $ 40,245     $ -     $ 4,048,000     $ (4,593,517 )   $ 3,459     $ (501,813 )
                                                         
                                                         
                                                         
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
          
                                                         
                                                         

 
F-3
 

CELL MEDX CORP.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(EXPRESSED IN US DOLLARS)
 
   
Six Months Ended
November 30,
  
   
2016
    
2015
  
             
Cash flows used in operating activities:
            
   Net loss
   $ (1,338,920 )   $ (1,509,042 )
Adjustments to reconcile net loss to net cash used in operating activities:
          
Accretion expense
     13,730       -  
Accrued interest on notes payable
     20,991       11,085  
Amortization
     36,521       6,500  
Consulting fees - non-cash
     -       20,364  
Foreign exchange gain
     (4,264 )     (8,190 )
Gain on sale of equipment
     -       (2,979 )
Loss on settlement of debt
     805,353       -  
Research and development costs - non-cash
     -       496,345  
Stock-based compensation
     78,203       606,866  
Changes in operating assets and liabilities:
                
Inventory
     797       (94 )
Other current assets
     (40,213 )     8,349  
Accounts payable
     12,358       81,663  
Accrued liabilities
     (29,553 )     (21,024 )
Unearned revenue     11,471       6,592  
Due to related parties
     30,221       140,525  
Net cash flows used in operating activities
     (403,305 )     (163,040 )
                 
Cash flows used in investing activities:
                
Acquisition of equipment
     (14,940 )     (32,838 )
Net cash used in investing activities
     (14,940 )     (32,838 )
                 
Cash flows provided by financing activities:
                
Advances payable
     2,684       (45,800 )
Proceeds from notes payable
     148,754       242,000  
Proceeds from subscription to shares
     357,500       -  
Net cash provided by financing activities
     508,938       196,200  
                 
Effects of foreign currency exchange on cash
     (274 )     (37 )
Increase in cash
     90,419       285  
Cash, beginning
     27,561       1,258  
Cash, ending
   $ 117,980     $ 1,543  
                 
Non-cash investing transactions:
                
Sale of equipment recorded as settlement of due to related parties
   $ -     $ 19,301  
                 
                 
The accompanying notes are an integral part of these unaudited interim consolidated financial statements.
  


 
F-4
 

CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2016
 

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS
 
Cell MedX Corp. (the “Company”) was incorporated under the laws of the State of Nevada. On November 26, 2014, the Company formed a subsidiary, Avyonce Cosmedics Inc., (“Avyonce”) and on April 26, 2016, the Company formed an additional subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”). Both subsidiaries were formed under the laws of British Columbia.
 
The Company is an early development stage company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.
 
Unaudited Interim Financial Statements
The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2016, included in the Company’s Annual Report on Form 10-K, filed with the SEC. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six month periods ended November 30, 2016, are not necessarily indicative of the results that may be expected for the year ending May 31, 2017.
 
Reclassifications
Certain prior period amounts in the accompanying unaudited consolidated interim financial statements have been reclassified to conform to the current period’s presentation.  These reclassifications had no net effect on the consolidated results of operations or financial position for any period presented.
 
Going Concern
The accompanying unaudited consolidated interim financial statements have been prepared assuming the Company will continue as a going concern. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations.  The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern.  These unaudited interim consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.  Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.

NOTE 2– RELATED PARTY TRANSACTIONS

Amounts due to related parties, other than notes payable to related parties (Notes 6 and 7) at November 30, 2016, and May 31, 2016:
   
November 30,
2016
    
May 31,
2016
  
Due to the Chief Executive Officer (“CEO”) and President
   $ 89,654     $ 66,254  
Due to the Vice President (“VP”), Corporate Strategy
     98,220       95,575  
Due to the VP, Technology and Operations
     59,958       56,596  
Due to the Chief Medical Officer
     81,059       81,059  
Due to a company owned by VP,  Corporate Strategy  and VP Technology and Operations
     1,704       1,747  
Due to the Chief Financial Officer (“CFO”)
     3,177       6,419  
Due to related parties
   $ 333,772     $ 307,650  
Amounts are unsecured, due on demand and bear no interest.

 
F-5
 
 

CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2016
 
During the six months ended November 30, 2016 and 2015, the Company had the following transactions with related parties:

   
November 30,
2016
    
November 30,
2015
  
Management fees incurred to the CEO and President
   $ 21,600     $ 21,600  
Stock-based compensation  incurred to the CEO and President (Note 8)
     11,600       446,942  
Management fees incurred to the CFO
     6,000       6,000  
Consulting fees incurred to the VP, Corporate Strategy
     25,178       55,669  
Consulting fees incurred to the VP, Technology and Operations
     25,178       43,768  
Net payments received  for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy
     -       (19,301 )
Value of options  issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8)
     -       496,345  
Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs
     -       50,000  
Stock-based compensation  incurred to the Chief Medical Officer (Note 8)
     66,603       159,924  
Research and development costs incurred to a company  controlled by the Chief Medical Officer
     -       25,700  
Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6)
     5,549       -  
Accretion expense associated with a term loan entered into with significant shareholder (Note 7)
     13,730       -  
Total transactions with related parties
   $ 175,438     $ 1,286,647  

On September 26, 2016, the Company entered into a letter agreement (the “Letter Agreement”) with Jean Arnett and Brad Hargreaves to cancel the unvested portion of the options granted to Ms. Arnett and Mr. Hargreaves by the Company (Note 8). In addition, the Company renegotiated its consulting arrangements with Ms. Arnett and Mr. Hargreaves. Based on the Letter Agreement, the Company has agreed to pay each of Ms. Arnett and Mr. Hargreaves CAD$5,000 per month, beginning effective August 1, 2016, for duration of six months.

NOTE 3 – EQUIPMENT

Amortization schedule for the equipment at November 30, 2016, and May 31, 2016:
 
   
November 30, 2016
    
May 31, 2016
  
Book value, beginning of the period
   $ 207,083     $ 25,846  
Changes during the period
     15,111       201,840  
Amortization
     (36,521 )     (20,603 )
Book value, end of the period
   $ 185,673     $ 207,083  

NOTE 4 – INVENTORY

As at November 30, 2016, the inventory consisted of supplies held for resale, and was valued at $3,715 (May 31, 2016 - $4,599). The Company uses lower of cost or net realizable value to determine the book value of the inventory at reporting date.

 
F-6
 
CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2016

NOTE 5 – UNEARNED REVENUE

On September 14, 2016, the Company received a $11,172 (CAD$15,000) deposit.
 
NOTE 6 – NOTES AND ADVANCES PAYABLE

The tables below summarize the short-term loans and advances outstanding as at November 30, 2016, and May 31, 2016:
 
As at November 30, 2016
Principal Outstanding
Interest Rate
per Annum
 
Accrued
Interest / Accretion
Total Book
Value
$      49,151
6%
Non-convertible
$         1,031
$        50,182
32,295
6%
Related Party (Note 2)
663
32,958
50,000
6%
Term Loan- Related Party (Notes 2 and 7)
18,758
43,758
3,230
0%
Advances
-
3,230
$    134,676
    
$       20,452
$      130,128

 
As at May 31, 2016
Principal Outstanding
Interest Rate
per Annum
 
Accrued
Interest / Accretion
Total Book
Value
      $    195,000
6%
Convertible
  $        18,588
$       213,588
490,000
6%
Non-convertible
12,842
502,842
197,000
6%
Related Party (Note 2)
7,620
204,620
50,000
6%
Term Loan- Related Party (Notes 2 and 7)
5,028
30,028
638
0%
Advances
-
638
$    932,638
    
$       44,078
$      951,716
.
During the six-month period ended November 30, 2016, the Company entered into a number of loan agreements for $75,000 (May 31, 2016 - $480,000). These loans bare interest at 6% per annum, are unsecured and payable on demand. During the same period, the Company entered into a number of loan agreements with Mr. Richard Jeffs (“Mr. Jeffs”), a major shareholder, for a total of $73,754 (CAD$96,500) (May 31, 2016 – $247,000). The loans of CAD$96,500 bear interest at 6% per annum, are unsecured and are payable on demand.

On September 30, 2016, Mr. Jeffs notified the Company that he had assigned all rights to his claims against the Company in the amount of $250,000 to two unaffiliated parties. The assignees notified the Company of their intention to convert the debt acquired by them from Mr. Jeffs into the units of the Company’s common stock as part of the non-brokered private placement offering (the “Offering”), which the Company closed on October 12, 2016 (Note 8).

On October 12, 2016, as part of its Offering, the Company settled a total of $1,006,691 owed under the notes payable (the “Debt”), which consisted of $949,001 in principal and $57,690 in accrued interest. The Debt was converted to 6,711,272 units of the Company's common stock at $0.15 per unit. Each unit consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year. The Company recorded a loss on settlement of $805,353, which resulted from the difference between the fair market value of the stock at the date of the conversion being $0.27 per share, and price of the unit offered as part of the private placement being $0.15 per unit.

As of November 30, 2016, the Company recorded $20,991 (2015 - $11,085) in interest expense associated with above loans.
 
F-7
 
CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2016
 
NOTE 7 – TERM LOAN

On March 3, 2016, the Company entered into a loan agreement (the “Term Loan Agreement”) with Mr. Jeffs for a loan in the principal amount of $50,000 maturing March 3, 2017, with interest payable at a rate of 6% per annum (the “Term Loan”).  As additional consideration for the Term Loan, the Company issued to Mr. Jeffs share purchase warrants (the “Warrants”) for the purchase of up to 2,000,000 shares of the Company’s common stock, exercisable for a period of five years at a price of $0.15 per share if exercised during the first year, $0.25 per share if exercised during the second year, $0.40 per share if exercised during the third year, $0.60 per share if exercised during the fourth year and $0.75 per share during the fifth year. The Warrants were determined to be detachable from the debt instrument, as the debt instrument does not have to be surrendered to exercise the warrant. Under the guidance provided by ASC 470-20-25-2, proceeds from the sale of debt instrument with stock purchase warrants must be allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the warrants was $25,000 and was recorded to additional paid-in capital.

The Term Loan has effective interest rate of 77.51%, which was due primarily to the recording of non-cash accretion interest. During the six-month period ended November 30, 2016, the Company recognized accretion expense of $13,730 (2015 - $Nil).

At March 3, 2016, the fair value of Warrants was valued using the Black-Scholes Option pricing model using the following assumptions:

 
At March 3, 2016
Expected Warrant Life
5 years
Risk-Free Interest Rate
1.33%
Expected Dividend Yield
Nil
Expected Stock Price Volatility
16%
 
NOTE 8 – SHARE CAPITAL

In January 2015 the Company received a subscription to 150,000 units (each a “Unit”) at a price of $0.50 per Unit for total proceeds of $75,000. Each Unit consisted of one share of the Company’s common stock and one warrant for the purchase of one additional share of the Company’s common stock, exercisable at a price of $1.00 per share, expiring on December 31, 2015. The Company issued the shares on September 20, 2016. Since the expiration date of the warrants had passed, the warrants were not issued.

On October 12, 2016, the Company closed its Offering at a price of $0.15 per unit, by issuing 2,383,333 units for cash proceeds of $357,500 and 6,711,272 units to the holders of the Company’s notes payable (Note 6) for debt settlement of $1,006,691. Each unit sold under the Offering consisted of one common share of the Company and one share purchase warrant expiring on October 12, 2021, and entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.

Options

On November 25, 2014, as part of the technology purchase agreement dated for reference October 16, 2014, and as amended on October 28, 2014 and November 13, 2014, the Company issued to the vendors of the Technology (the “Vendors”) options for the purchase of up to 20,000,000 shares of the Company’s common stock at an initial exercise price of $0.05 per share and expiring on the 5th year anniversary of the applicable vesting date, or on December 31, 2019, for those options that have not vested.

On August 26, 2015, the board of directors of the Company determined that the options to purchase up to 2,500,000 common shares of the Company’s common stock granted to the Vendors for the Technology, which were to vest upon the design and commencement of the first clinical trial, have vested. The total fair value of the vested options was calculated to be $496,345 (Note 2) and was determined using the Black-Scholes Option pricing model at the grant date using the following assumptions:

                                                                              
At August 26, 2015
Expected Life of Options
5 years
Risk-Free Interest Rate
1.49%
Expected Dividend Yield
Nil
Expected Stock Price Volatility
216%
 
On September 26, 2016, the Company entered into a letter agreement with the Vendors to cancel remaining 17,500,000 options (Note 2).
 
 
F-8
 
 
CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2016
 
On January 13, 2015, the Company issued 2,400,000 non-transferrable options to its Chief Medical Officer. The options are exercisable at $0.67 per share and vest quarterly starting on March 31, 2015, in equal portions of 200,000 shares per vesting period, and expire on the 5th year anniversary of the applicable vesting date.
 
The total fair value of the options was calculated to be $591,503 and was determined using the Black-Scholes Option pricing model at the grant date using the following assumptions:

 
At January 13, 2015
Expected Life of Options
5 years from vesting
Risk-Free Interest Rate
1.37%
Expected Dividend Yield
Nil
Expected Stock Price Volatility
27%

As of November 30, 2016, options to acquire up to 1,400,000 shares of the Company’s common stock have vested, and the Company recognized $66,603 (2015 - $159,924) (Note 2) as stock-based compensation expense for the six-month period ended November 30, 2016. Further $58,197 will be recognized in the future periods.

On August 5, 2015, the Company issued to its CEO, President and a member of the board of directors options to purchase up to 2,500,000 shares of the Company’s common stock (the “CEO Options”). The CEO Options are exercisable at $0.35 per share. As of November 30, 2016, all CEO Options have vested.

The CEO Options expire on the 5th year anniversary of the particular vesting date, subject to certain early termination provisions, upon the death of the optionee, or if the optionee ceases to act for the Company in any capacity either voluntarily or as a result of a termination or removal for cause.

The total fair value of the options was calculated to be $616,886 and was determined using the Black-Scholes option pricing model at the grant date using the following assumptions:

 
At August 5, 2015
Expected Life of Options
5 years from vesting
Risk-Free Interest Rate
1.65%
Expected Dividend Yield
Nil
Expected Stock Price Volatility
218%

During the six-month period ended November 30, 2016, the Company recognized $11,600 as share-based compensation expense (2015 - $446,942) (Note 2).

The changes in the number of stock options outstanding during the six-month period ended November 30, 2016, and for the year ended May 31, 2016, are as follows:

   
Six months ended
November 30, 2016
    
Year ended
May 31, 2016
  
   
Number of options
    
Weighted average exercise price
    
Number of options
    
Weighted average exercise price
  
Options outstanding, beginning
     25,050,000     $ 0.14       22,400,000     $ 0.12  
Options granted
     -       n/a       2,650,000     $ 0.34  
Options cancelled
     (17,500,000 )   $ 0.05       -       n/a  
Options outstanding, ending
     7,550,000     $ 0.35       25,050,000     $ 0.14  
Options exercisable, ending
     6,550,000     $ 0.30       5,650,000     $ 0.27  
 
 
F-9
 
 
CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2016

Details of options outstanding and exercisable as at November 30, 2016, are as follows:

Exercise price
Grant date
Number of options
granted
Number of options
exercisable
$0.05
November 25, 2014
2,500,000
2,500,000
$0.67
January 13, 2015
2,400,000
1,400,000
$0.35
August 5, 2015
2,500,000
2,500,000
$0.20
September 23, 2015
150,000
150,000
   
7,550,000
6,550,000

At November 30, 2016, the weighted average remaining contractual life of the stock options outstanding and exercisable was 3.89 years.

Warrants

On March 3, 2016, the Company issued non-transferrable share purchase warrants to acquire up to 2,000,000 shares of the Company’s common stock expiring on March 3, 2021, to Mr. Jeffs as additional consideration for the Term Loan (Note 7). The exercise price of these warrants is as follows:

Period expiring on:
Exercise Price
March 3, 2017
$0.15
March 3, 2018
$0.25
March 3, 2019
$0.40
March 3, 2020
$0.60
March 3, 2021
$0.75
 
On October 12, 2016, as part of the Offering, the Company issued warrants to acquire up to 9,094,605 of the Company’s common stock expiring on October 12, 2021. The exercise price of these warrants is as follows:

Period expiring on:
Exercise Price
October 12, 2017
$0.50
October 12, 2018
$0.75
October 12, 2019
$1.00
October 12, 2020
$1.25
October 12, 2021
$1.50

 
F-10
 
 
CELL MEDX CORP.
NOTES TO THE UNAUDITED INTERIM
CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
NOVEMBER 30, 2016
 
The changes in the number of warrants outstanding during the six-month period ended November 30, 2016, and for the year ended May 31, 2016, are as follows:

 
Six months ended
November 30, 2016
Year ended
May 31, 2016
Warrants outstanding, beginning
-
-
Warrants issued
11,094,605
-
Warrants outstanding, ending
11,094,605
-
 
Details of warrants outstanding as at November 30, 2016, are as follows:
 
Exercise price
Expiry Date
Number of warrants
exercisable
$0.15 1st year; $0.25 2nd year; $0.40 3rd year;
$0.60 4th year; $0.75 5th year
March 3, 2021
2,000,000
$0.50 1st year; $0.75 2nd year; $1.00 3rd year
$1.25 4th year; $1.50 5th year
October 12, 2021
9,094,605
   
11,094,605
 
At November 30, 2016, the weighted average remaining contractual life of the share purchase warrants was 4.76 years.
 
NOTE 9 – SUBSEQUENT EVENTS

a)  
Subsequent to November 30, 2016, the Company received 20 eBalance Pro wellness devices.  The Company paid the developer $93,764 (EURO 86,776) for the devices.  

b)  
In January 2017 the Company received CAD$40,000 under loan agreements with a non-related party, and CAD$15,000 under a loan agreement with Mr. Richard Jeffs. The loans bear interest at 6% per annum, are unsecured and payable on demand (Note 6).

 
F-11
 

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited interim consolidated financial statements, the notes to those financial statements and other financial information appearing elsewhere in this document. In addition to historical information, the following discussion and other parts of this document contain forward-looking statements that reflect plans, estimates, intentions, expectations and beliefs. Actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those set forth in the "Risk Factors" in Part II, Item 1A of this Quarterly Report.

The discussion provided in this Quarterly Report should be read in conjunction with our Annual Report on Form 10-K for the year ended May 31, 2016, filed with the United States Securities and Exchange Commission (the “SEC”) on September 13, 2016.

Overview

We were incorporated as Plandel Resources, Inc. under the laws of the State of Nevada on March 19, 2010. On March 24, 2014, we changed our name to Sports Asylum, Inc. and on September 30, 2014, we changed our name to Cell MedX Corp. to reflect our current business direction.

On November 25, 2014, we completed the acquisition of a proprietary method for the application of bioelectric signaling to treat diabetes and related ailments (the “eBalance Technology”).  With our acquisition of the eBalance Technology, we have shifted our business direction to the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.

On November 26, 2014, we formed a subsidiary, Avyonce Cosmedics Inc., (the “Avyonce”) under the laws of the Province of British Columbia. Avyonce’s main business activity is channelled towards the resale and marketing of spa technology and equipment to the worldwide beauty and wellness industry.

On April 26, 2016, we formed a subsidiary, Cell MedX (Canada) Corp., (the “Cell MedX Canada”) under the laws of the Province of British Columbia, in anticipation of increased business activity in Canada.

Recent Corporate Developments

The following corporate developments occurred during the quarter ended November 30, 2016, and up to the date of the filing of this report:

Letter Agreement with Jean Arnett and Brad Hargreaves
 
On September 26, 2016, we entered into a letter agreement (the “Letter Agreement”) with Jean Arnett and Brad Hargreaves to, among other things, cancel the unvested portion of the options granted to Ms. Arnett and Mr. Hargreaves pursuant to those separate Option Agreements between us and Ms. Arnett, and Mr. Hargreaves, each dated for reference November 25, 2014 (the “Cancelled Options”).  The Cancelled Options had previously entitled Ms. Arnett and Mr. Hargreaves to collectively acquire up to 17,500,000 common shares of the Company (8,750,000 shares, each) at an initial price of $0.05 per share.

In addition, we renegotiated our consulting arrangements with Ms. Arnett and Mr. Hargreaves. Based on the Letter Agreement, we agreed to pay each of Ms. Arnett and Mr. Hargreaves CAD$5,000 per month, beginning effective August 1, 2016, for a duration of six (6) months.

Appointment of Director

On September 26, 2016, the board of directors of the Company unanimously resolved to fix the number of directors at three, and appointed Yanika Silina, our current Chief Financial Officer, as a director to fill the vacancy created by the increase in the number of directors. We did not enter into any new compensation arrangements with Ms. Silina in connection with her appointment as a director of the Company.
 
Private Placement Offering

On October 12, 2016, we closed a non-brokered private placement offering (the “Offering”) at a price of $0.15 per unit, by issuing 2,383,333 units for cash proceeds of $357,500 and 6,711,272 units to the holders of our notes payable for debt settlement of $1,006,691. Each unit sold under the Offering consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.

Loan Agreements
 
During the quarter ended November 30, 2016, we did not enter into any loan agreements, subsequent to November 30, 2016, we entered into loan agreements for a total of CAD$55,000, of which CAD$15,000 were loaned to us by Mr. Richard Jeffs, our major shareholder. The loans bear interest at 6% per annum, compounded monthly, are unsecured and payable on demand.

On September 30, 2016, Mr. Jeffs notified us that he had assigned all rights to his claims against the Company in the amount of $250,000 to two unaffiliated parties (the “Assignees”). The full amount of debt assigned to the Assignees was converted into the units of the Company’s common stock as part of the Offering.

 
4
 
Appointment of a Member of Advisory Board and a Distributor
 
On November 16, 2016, the Company appointed Gregory Pek to the Company’s advisory board and as a distributor for Hong Kong and the Philippines. Mr. Pek will assist the Company in a wide range of functions including, but not limited to, input into the structure of the observational clinical studies and developing marketing strategies in Asia, overall business strategy, and financing.
 
Update on Observational Clinical Study
 
During the period ended November 30, 2016, the Company, with the assistance of Nutrasource Diagnostics Inc., has secured the main research facility in Hamilton, Ontario, completed an investigational protocol as well as Informed Consent and Ethics Board submission documentation, in an anticipation to enter regulated clinical trials (the “Study”). The Company received Health Canada’s approval to commence the Study on January 12, 2017. The detailed information of the Study will be posted on clinicaltrials.gov upon approval of government regulatory agencies.
 
eBalance Pro Wellness Devices
 
In December 2016 the Company received the first shipment of its eBalance Pro wellness devices. The Company plans to use several of these devices in its observations and in the Study, as well as for securing Medical CE Marking in Europe.
 
Results of Operations for the Three and Six Months Ended November 30, 2016 and 2015

Our operating results for the three and six month periods ended November 30, 2016 and 2015, and the changes in the operating results between those periods are summarized in the table below.
 
   
Three Months Ended
          
Six Months Ended
        
   
November 30,
2016
    
November 30,
2015
    
Percentage
Change
    
November 30,
2016
    
November 30,
2015
    
Percentage
Change
  
                                     
Sales
   $ 336     $ 3,767       (91.1 )%   $ 5,704     $ 5,649       1.0 %
Cost of goods sold
     180       2,897       (93.8 )%     3,591       4,102       (12.5 )%
Gross margin
     156       870       (82.1 )%     2,113       1,547       36.6 %
Operating expenses
                                                
Amortization
     18,510       2,587       615.5 %     36,521       6,500       461.9 %
Consulting fees
     75,607       103,252       (26.8 )%     150,747       189,710       (20.5 )%
General and administrative expenses
     51,239       52,721       (2.8 )%     95,463       120,683       (20.9 )%
Research and development costs
     67,173       25,185       166.7 %     140,025       578,724       (75.8 )%
Stock-based compensation
     29,306       290,281       (89.9 )%     78,203       606,866       (87.1 )%
Total operating expenses
     241,835       474,026       (49.0 )%     500,959       1,502,483       (66.7 )%
Accretion expense
     (7,473 )     -       n/a       (13,730 )     -       n/a  
Gain on sale of equipment
     -       -       n/a       -       2,979       (100.0 )%
Interest
     (5,596 )     (6,458 )     (13.3 )%     (20,991 )     (11,085 )     89.4 %
Loss on settlement of debt
     (805,353 )     -       n/a       (805,353 )     -       n/a  
Net loss
   $ (1,060,101 )   $ (479,614 )     121.0 %   $ (1,338,920 )   $ (1,509,042 )     (11.3 )%

 
5
 

Revenues

Our revenue during the three-month period ended November 30, 2016, and during the comparative period ended November 30, 2015, consisted of sales of consumables for the spa industry. During the six-month period ended November 30, 2016 and 2015, our revenue consisted of sales of spa equipment, consumables and services. Due to the current concentration on research and development of our eBalance Technology and devices based on this technology, we do not expect to have significant operating revenue in the foreseeable future.

Operating Expenses

During the three-month period ended November 30, 2016, our operating expenses decreased by 49% from $474,026 incurred during the three months ended November 30, 2015, to $241,835 incurred during the three months ended November 30, 2016. The decrease was mainly associated with reduced consulting fees, mainly to Ms. Arnett and Mr. Hargreaves, as well as the decrease in stock-based compensation, mainly due to vesting terms of the options granted during our Fiscal 2015 and 2016. These reductions were in part offset by increases to our research and development fees, as well as the amortization we recorded on equipment we use in our observational trials.

During the six-month period ended November 30, 2016, our operating expenses decreased by 66.7% from $1,502,483 incurred during the six months ended November 30, 2015, to $500,959 incurred during the six months ended November 30, 2016. The most significant year-to-date changes were as follows:

●
Our research and development fees for the six-month period ended November 30, 2016, decreased by $438,699, from $578,724 we incurred during the six months ended November 30, 2015 to $140,025 we incurred during the six months ended November 30, 2016. The higher research and development fees during the comparative period were directly attributed to $496,345 we recorded as fair value of options to acquire up to 2,500,000 shares of our common stock which we granted to Ms. Arnett and Mr. Hargreaves in connection with our acquisition from them of the eBalance Technology pursuant to our Technology Purchase Agreement, as amended.
●
Our stock-based compensation for the six-month period ended November 30, 2016, decreased by $528,663, from $606,866 we incurred during the six months ended November 30, 2015 to $78,203 we incurred during the six months ended November 30, 2016. The stock-based compensation included $66,603 (2015 - $159,924) in fair market value of the options we granted to Dr. Sanderson pursuant to his consulting agreement with us, and $11,600 (2015 - $446,942) in fair market value of the options we granted to Mr. McEnulty pursuant to his option agreement with us.
●
During the six-month period ended November 30, 2016, our consulting fees decreased by $38,963, from $189,710 we incurred during the six months ended November 30, 2015, to $150,747 we incurred during the six months ended November 30, 2016. The decrease was mainly associated with a change in consulting arrangements with Ms. Arnett and Mr. Hargreaves - the vendors of our eBalance Technology and our officers.
●
Our general and administrative fees for the six-month period ended November 30, 2016, decreased by $25,220, or 20.9%, from $120,683 we incurred during the six months ended November 30, 2015 to $95,463 we incurred during the six months ended November 30, 2016. The largest factors that contributed to this decrease were associated with a reduction in our corporate communication fees of $9,459, accounting and audit fees of $9,822, rent of $12,820, and salaries and wages of $7,480. These decreases were in part offset by increases in travel fees of $15,172, loss on foreign exchange of $1,968, and professional fees of $1,594.
●
During the six-month period ended November 30, 2016, we recorded $36,521 in amortization on our equipment used in observations and research and development. During the comparative period ended November 30, 2015, our amortization expense was $6,500.

Other Items

●
During the six-month period ended November 30, 2016, we accrued $20,991 (2015 - $11,085) in interest associated with the outstanding notes payable. Of this interest, $5,549 was accrued on notes payable we issued to Mr. Jeffs, our major shareholder.
●
During the six-month period ended November 30, 2015, we recorded $2,979 in a gain on sale of equipment which we sold to Mr. Hargreaves for total proceeds of $19,301. We did not have similar transactions during the six-month period ended November 30, 2016.
●
During the six-month period ended November 30, 2016, we recorded $13,730 (2015 - $Nil) in accretion expense which resulted from the difference between the 6% stated interest rate and the 77.51% implied interest rate we used to determine the fair value of the proceeds we received pursuant to the $50,000 term loan with Mr. Jeffs.
●
During the six-month period ended November 30, 2016, we recorded $805,353 (2015 - $Nil) in loss on settlement of debt when our debt holders chose to convert $1,006,691 owed to them into units of our common stock as part of the non-brokered private placement financing we closed on October 12, 2016 (the “Offering”). The loss resulted from the difference between the conversion price, being $0.15 per unit, and the fair market value of our common stock on the closing of the Offering, being $0.27 per share.


 
6
 

Liquidity and Capital Resources

Working Capital
   
As at
    
As at
        
   
November 30,
2016
    
May 31,
2016
    
Percentage
Change
  
Current assets
   $ 192,834     $ 61,844       211.8 %
Current liabilities
     880,320       1,681,479       (47.6 )%
Working capital deficit
   $ (687,486 )   $ (1,619,635 )     (57.6 )%

As of November 30, 2016, we had a cash balance of $117,980, a working capital deficit of $687,486 and cash flows used in operations of $403,305 for the period then ended. During the six-month period ended November 30, 2016, we funded our operations with $357,500 we received from subscriptions to the units of our common stock we issued as part of our Offering, $73,754 (CAD$96,500) we received from Mr. Jeffs, our major shareholder, and with $75,000 we received from non-related parties. See “Net Cash Provided By Financing Activities”.

We did not generate sufficient cash flows from our operating activities to satisfy our cash requirements for the period ended November 30, 2016.  The amount of cash that we have generated from our operations to date is significantly less than our current debt obligations, including our debt obligations under our remaining notes payable.  There is no assurance that we will be able to generate sufficient cash from our operations to repay the amounts owing under these notes and advances payable, or to service our other debt obligations.  If we are unable to generate sufficient cash flow from our operations to repay the amounts owing when due, we may be required to raise additional financing from other sources. The outcome of these matters cannot be predicted with any certainty at this time and rasies substantial doubt that we will be able to continue as a going concern.

Cash Flows
   
Six months ended
  
   
November 30,
2016
    
November 30,
2015
  
Cash flows used in operating activities
   $ (403,305 )   $ (163,040 )
Cash flows used in investing activities
     (14,940 )     (32,838 )
Cash flows provided by financing activities
     508,938       196,200  
Effects of foreign currency exchange on cash
     (274 )     (37 )
Net increase in cash during the period
   $ 90,419     $ 285  

Net Cash Used in Operating Activities

Net cash used in operating activities during the six months ended November 30, 2016, was $403,305. This cash was primarily used to cover our cash operating expenses of $388,386, to increase our current assets by $40,213, which included partial payments we made on manufacturing of our eBalance Pro Wellness devices, and to reduce our accrued liabilities by $29,553. These uses of cash were offset by decrease in our inventory of $797, and by increases in our accounts payable and amounts due to related parties of $12,358 and $30,221, respectively. In addition, we recorded $11,471 in unearned revenue associated with the deposit we received on the eBalance Pro Wellness device, which we received in December 2016.

Net cash used in operating activities during the six months ended November 30, 2015, was $163,040. This cash was primarily used to cover our cash operating expenses of $379,051, and to increase our inventory and decrease the accrued liabilities by $94 and $21,024, respectively. These uses of cash were offset by decreases in other current assets of $8,349, and increases in our accounts payable and amounts due to related parties of $81,663 and $140,525, respectively. In addition, we received $6,592 as payments for the spa equipment, which we recorded as unearned revenue pending delivery of the equipment to our customers.

 
7
 
Non-cash transactions

During the six-month period ended November 30, 2016, our net loss was affected by the following expenses that did not have any impact on cash used in operations:
 
·
  
$805,353 in loss on settlement of debt we recorded when our debt holders chose to convert $1,006,691 owed to them into units of our common stock as part of the Offering. The loss resulted from the difference between the conversion price, being $0.15 per unit, and the fair market value of our common stock on the closing of the Offering, being $0.27 per share.
·
  
$78,203 in stock-based compensation, of which $66,603 was associated with the fair value of the options to purchase up to 2,400,000 shares of our common stock we granted to Dr. Sanderson as compensation for his appointment as our Chief Medical Officer; and $11,600 was associated with the fair value of the options to purchase up to 2,500,000 shares of our common stock we granted to Mr. Frank McEnulty, our CEO and President;
·
  
$20,991 in interest we accrued on the outstanding notes payable. Of this interest, $5,549 was accrued on the notes payable we issued to Mr. Jeffs, our major shareholder;
·
  
$13,730 in accretion expense which resulted from the difference between the 6%  stated interest rate and the 77.51% implied interest rate we used to determine the fair value of the proceeds we received pursuant to the $50,000 term loan with Mr. Jeffs; and
·
  
$36,521 in amortization expense we recorded on the equipment we use in our research of the eBalance Technology.
 
The above expenses were in part offset by $4,264 decrease in the loss on foreign exchange, which resulted from fluctuations of Canadian dollar and European Euro denominated transactions.

During the six-month period ended November 30, 2015, our net loss was affected by the following amounts that did not have any impact on cash used in operations:

·
  
$6,500 in amortization expense we recorded on the equipment that is being used in our research of the eBalance Technology;
·
  
$606,866 in stock-based compensation, of which $159,924 was associated with the fair value of the options to purchase up to 2,400,000 shares of our common stock we granted to Dr. Sanderson as compensation for his appointment as our Chief Medical Officer; and $446,942 was associated with the fair value of the options to purchase up to 2,500,000 shares of our common stock we granted to Mr. Frank McEnulty, our CEO and President;
·
  
$496,345 in stock-based compensation associated with the fair value of the options to purchase up to 2,500,000 shares of our common stock, which we granted to Ms. Arnett and Mr. Hargreaves as part of the options to purchase up to 20,000,000 shares of our common stock pursuant to our Technology Purchase Agreement, dated for reference November 25, 2014, which vested on August 26, 2015; and
·
  
$20,364 in stock-based compensation associated with the fair value of the options to purchase up to 150,000 shares of our common stock, which we granted to Mr. Bulwa, as part of his Consulting Agreement with us.
 
The above expenses were in part offset by the following non-cash transactions:
 
·
  
$8,190 decrease in the loss on foreign exchange, which resulted from fluctuations of Canadian dollar and European Euro denominated transactions; and
·
  
$2,979 gain we recorded on the sale of our equipment to Ms. Arnett and Mr. Hargreaves; $19,301 in proceeds from the sale were used to reduce amounts owed to Mr. Hargreaves and Ms. Arnett for services they provided to the Company.

Net Cash Provided by Financing Activities

During the six-month period ended November 30, 2016, we borrowed a total of $75,000 from unrelated parties and $73,754 (CAD$96,500) from our major shareholder. These loans were unsecured, payable on demand and bore interest at 6% per annum, compounded monthly. In addition to the loans, we received $2,684 in non-interest bearing advances from an unrelated party.   During the same period we received $357,500 from subscriptions to the units of our common stock under the Offering, which we closed on October 12, 2016.

During the six months ended November 30, 2015, we borrowed a total of $242,000 from unrelated parties.  The loans were unsecured, payable on demand and bore interest at 6% per annum, compounded monthly. During the same period we repaid $45,800 in non-interest bearing advances to a non-related party.

 
8
 
Net Cash Used in Investing Activities

During the six-month period ended November 30, 2016, we paid $14,940 for the equipment which is being used in our observational studies.

During the six-month period ended November 30, 2015, we paid $32,838 for the equipment which is being used in our ongoing research and development of the eBalance Technology and devices as well as in our observational studies.

Going Concern

The notes to our unaudited interim consolidated financial statements at November 30, 2016, disclose our uncertain ability to continue as a going concern. We are development stage company with limited operations. To date we have been able to generate only minimal revenue from the operations of our wholly owned subsidiary, Avyonce. Our research and development plans for the near future will require large capital expenditures, which we are planning to mitigate through equity or debt financing.

We have accumulated a deficit of $4,593,517 since inception and increased financing will be required to fund and support our operations. Our continuation as a going concern depends upon the continued financial support of our shareholders, our ability to obtain necessary debt or equity financing to continue operations, and the attainment of profitable operations. Our unaudited interim consolidated financial statements do not give effect to any adjustments that would be necessary should we be unable to continue as a going concern and therefore be required to realize our assets and discharge our liabilities in other than the normal course of business and at amounts different from those reflected in our financial statements.
 
Off-Balance Sheet Arrangements

None.

Critical Accounting Policies
 
An appreciation of our critical accounting policies is necessary to understand our financial results. These policies may require management to make difficult and subjective judgments regarding uncertainties, and as a result, such estimates may significantly impact our financial results. The precision of these estimates and the likelihood of future changes depend on a number of underlying variables and a range of possible outcomes. We have applied our critical accounting policies and estimation methods consistently.
 
Changes in and Disagreements with Accountants on Accounting Procedures and Financial Disclosure
 
None.

Item 3.  Quantitative and Qualitative Disclosure about Market Risk
 
None
 
Item 4.  Controls and Procedures
 
Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of November 30, 2016. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective in recording, processing, summarizing and reporting information required to be disclosed within the time periods specified in Securities and Exchange Commission’s rules and forms due to lack of segregation of duties.

During the quarter ended November 30, 2016, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.
 
9
 

PART II — OTHER INFORMATION
 
Item 1.  Legal Proceedings
 
None.
 
Item 1A.  Risk Factors
 
There is a high degree of risk associated with investing in our securities.  Prospective investors should carefully read this Quarterly Report on Form 10-Q and consider the following risk factors when deciding whether to purchase our securities.
 
The risk factors outlined below are some of the known, substantial, material and potential risks that could adversely affect our business, financial condition, operating results and common share value. We cannot assure that we will successfully address these or any unknown risks and a failure to do so can have a negative impact on your investment.  We may encounter risks in addition to those described below. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, may also impair or adversely affect our business, financial condition or results of operation.
 
Risks Associated with our Company and our Industry
 
We operate in a highly competitive market. We face competition from large, well established medical device manufacturers and pharmaceutical companies in the market for treating and managing diabetes and related ailments.  Many of these companies are very well accepted by health practitioners and have significant resources, and we may not be able to compete effectively.
 
The market for devices and therapies for treating and managing diabetes and related ailments is intensely competitive, subject to rapid change and significantly affected by new product introductions. We compete indirectly with large pharmaceutical and medical device companies, such as Bayer Corp., Becton Dickinson Corp., LifeScan Inc., a division of Johnson & Johnson, MediSense Inc. and TheraSense Inc. These competitors’ products are based on traditional healthcare model and are well accepted by health practitioners and patients. If these companies decide to penetrate our target market they could threaten our position in the market.
 
We are subject to numerous governmental regulations which can increase our costs of developing our eBalance Technology and products based on this technology.
 
Our products may be subject to rigorous regulation by the FDA, Health Canada and numerous international, supranational, federal, and state authorities. The process of obtaining regulatory approvals to market a medical device can be costly and time-consuming, and approvals might not be granted for future products, or additional indications or uses of existing products, on a timely basis, if at all. Delays in the receipt of, or failure to obtain approvals for, our products, or new indications and uses, could result in delayed realization of product revenues, reduction in revenues, and in substantial additional costs. In addition, no assurance can be given that we will remain in compliance with applicable FDA, Health Canada and other regulatory requirements once approval or marketing authorization has been obtained for a product. These requirements include, among other things, regulations regarding manufacturing practices, product labeling, and advertising and post-marketing reporting, including adverse event reports and field alerts due to manufacturing quality concerns.
 
Changes in the health care regulatory environment may adversely affect our business.
 
A number of the provisions of the U.S. Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 and its amendments changed access to health care products and services and established new fees for the medical device industry. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.
 
Competitors' intellectual property may prevent us from selling our products or have a material adverse effect on our future profitability and financial condition.
 
Competitors may claim that our Technology infringes upon their intellectual property. Resolving an intellectual property infringement claim can be costly and time consuming and may require us to enter into license agreements. We cannot guarantee that we would be able to obtain license agreements on commercially reasonable terms. A successful claim of patent or other intellectual property infringement could subject us to significant damages or an injunction preventing the manufacture, sale or use of our product. Any of these events could have a material adverse effect on our profitability and financial condition.
 
Our research and development efforts may not result in the development of commercially successful products based on our eBalance Technology, which may hinder our profitability and future growth.
 
Our eBalance Technology is currently in the research and development stage as are our planned products incorporating this technology.  In order to develop commercially marketable products, we will be required to commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. We must make ongoing substantial expenditures without any assurance that our efforts will be commercially successful. Failure can occur at any point in the process, including after significant funds have been invested. Planned products may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others.
 
Even if we successfully develop marketable products or commercially develop our current technology, we may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations.
 
Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether our products under development will be launched, whether we will be able to develop, license, or otherwise acquire new products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, causing our revenues and operating results to suffer.
 
 
10
 
New products and technological advances by our competitors may negatively affect our results of operations.
 
Our products face intense competition from our competitors. Competitors' products may be safer, more effective, more effectively marketed or sold, or have lower prices or superior performance features than our products. We cannot predict with certainty the timing or impact of the introduction of competitors' products.
 
Significant safety concerns could arise for our products, which could have a material adverse effect on our revenues and financial condition.
 
Healthcare products typically receive regulatory approval based on data obtained in controlled clinical trials of limited duration. Following regulatory approval, these products will be used over longer periods of time in many patients. Investigators may also conduct additional, and perhaps more extensive, studies. If new safety issues are reported, we may be required to amend the conditions of use for a product. For example, we may be required to provide additional warnings on a product's label or narrow its approved intended use, either of which could reduce the product's market acceptance. If serious safety issues arise with our product, sales of the product could be halted by us or by regulatory authorities. Safety issues affecting suppliers' or competitors' products also may reduce the market acceptance of our products.
 
Inability to attract and maintain key personnel may cause our business to fail.
 
Success depends on the acquisition of key personnel.  We will have to compete with other companies both within and outside the healthcare industry to recruit and retain competent employees and consultants.  If we cannot maintain qualified personnel to meet the needs of our anticipated growth, we could face material adverse effects on our business and financial condition.
 
We are recently formed, lack an operating history and to date have generated only minimal revenues through our wholly owned subsidiary, Avyonce.  If we cannot increase our revenues to start generating profits, our investors may lose their entire investment.
 
We are a recently formed company and to date have generated only minimal revenues through sales of Spa equipment and services through our wholly owned subsidiary, Avyonce. No profits have been made to date and if we fail to make any then we may fail as a business and an investment in our common stock will be worth nothing.  We have no operating history and thus no way to measure progress or potential future success.  Success has yet to be proven. We have yet to prove our eBalance Technology through clinical trials and we have yet to develop any products through which we would be able to start generating revenue. Financial losses should be expected to continue in the near future and at least until such time that we enter commercial production of devices based on the eBalance Technology, of which there is no assurance.  As a new business we face all the risks of a ‘start-up’ venture including unforeseen costs, expenses, problems, and management limitations and difficulties.  Since inception, we have accumulated deficit of $4,593,517 and there is no guarantee, that we may ever be able to turn a profit or locate additional opportunities, hire additional management and other personnel.
 
We need to acquire additional financing or our business will fail.
 
We must obtain additional capital or our business will fail. In order to continue development of our eBalance Technology and to successfully complete clinical trials, we must secure more funds. Currently, we have very limited resources and have already accumulated a net loss. Financing may be subject to numerous factors including investor sentiment, acceptance of our technology and so on.  We currently have no arrangements for additional financing.  We may also have to borrow large sums of money that require substantial capital and interest payments.
 
Risks related to our stock
 
We expect to raise additional capital through the offering of more shares, which will result in dilution to our current shareholders.
 
Raising additional capital through future offerings of common stock is expected to be necessary for our Company to continue.  However there is no guarantee that we will be successful in raising additional capital. Issuance of additional stock will increase the total number of shares issued and outstanding resulting in decrease of the percentage interest held by each of our shareholders. 
 
There is a limited market for our common stock meaning that our shareholders may not be able to resell their shares.
 
Our common stock currently has a limited market which may restrict shareholders’ ability to resell their stock or use their stock as collateral. Thus, the shareholders may have to sell their shares privately which may prove very difficult. Private sales are more difficult and often give lower than anticipated prices.
 
Should a larger public market develop for our stock, future sales of shares may negatively affect their market price.
 
Even if a larger market develops, the shares may be sparsely traded and have wide share price fluctuations.  Liquidity may be low despite there being a market, making it difficult to get a return on the investment.  The price also depends on potential investor’s feelings regarding the results of our operations, the competition of other companies’ shares, our ability to generate future revenues, and market perception about future of microcurrent technologies.
 
Because our stock is a penny stock, stockholders will be more limited in their ability to sell their stock.
 
The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or quotation system.
 
 
11
 
Because our securities constitute "penny stocks" within the meaning of the rules, the rules apply to us and to our securities. The rules may further affect the ability of owners of shares to sell our securities in any market that might develop for them. As long as the quotation price of our common stock is less than $5.00 per share, the common stock will be subject to Rule 15g-9 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that:
 
·
  
contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;
·
  
contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements of securities laws;
·
  
contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price;
·
  
contains a toll-free telephone number for inquiries on disciplinary actions;
·
  
defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and
·
  
contains such other information and is in such form, including language, type, size and format, as the SEC shall require by rule or regulation.
 
The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with: (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our stock.
 
We have not paid nor anticipate paying cash dividends on our common stock.
 
We have not declared any dividends on our common stock during the past two fiscal years or at any time in our history.  The Nevada Revised Statutes (the “NRS”), provide certain limitations on our ability to declare dividends. Section 78.288 of Chapter 78 of the NRS prohibits us from declaring dividends where, after giving effect to the distribution of the dividend:
 
 
(a)
we would not be able to pay our debts as they become due in the usual course of business; or
 
(b)
except as may be allowed by our Articles of Incorporation, our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of the distribution, to satisfy the preferential rights upon dissolution of stockholders who may have preferential rights and whose preferential rights are superior to those receiving the distribution.
 
We do not expect to declare any dividends in the foreseeable future as we expect to spend any funds legally available for the payment of dividends on the development of our business.
 
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds

In January 2015 we received a subscription for 150,000 units (each a “Unit”) at a price of $0.50 per Unit for total proceeds of $75,000. Each Unit consisted of one share of our common stock and one warrant for the purchase of one additional share of our common stock, exercisable at a price of $1.00 per share, expiring on December 31, 2015. We issued the shares on September 20, 2016. Since the expiration date of the warrants had passed, the warrants were not issued.

On October 12, 2016, we closed a non-brokered private placement offering (the “Offering”) at a price of $0.15 per unit (each an “October Unit”), by issuing 9,094,605 October Units for total gross proceeds of $1,364,191.
 
Each October Unit sold under the Offering consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year. As part of the Offering, the holders of the notes payable, which were due on demand, chose to convert a total of $1,006,691 owed to them into October Units of the Company’s common stock.
 
7,195,958 October Units were issued pursuant to the provisions of Regulation S of the United States Securities Act of 1933, as amended (the “Act”) to the persons who are not residents of the United States and are otherwise not “U.S. Persons” as that term is defined in Rule 902(k) of Regulation S of the Act. Remaining 1,898,647 October Units were issued pursuant to the exemption from the registration requirements of the Securities Act of 1933 provided by Rule 506 of Regulation D on the basis of representations provided by the debt holder that it was an accredited investor, as that term is defined in Regulation D.
 
Item 3.  Defaults upon Senior Securities
 
None.
 
Item 4.  Mine Safety Disclosures
 
None.

Item 5.  Other Information
 
None.

 
12
 

Item 6.  Exhibits
 
Exhibit Number
  
Description of Document
3.1
  
Articles of Incorporation (2)
3.2
  
Articles of Merger – Sports Asylum, Inc. and Plandel Resources, Inc.(5)
3.3
  
Articles of Merger – Cell MedX Corp. and Sports Asylum, Inc.(5)
3.4
  
Bylaws (1)
4.1
  
Specimen Stock Certificate (1)
10.1
  
Letter Agreement dated August 29, 2014 among Sports Asylum, Inc., Jean Arnett, Brad Hargreaves and XC Velle Institute Inc. (4)
10.2
  
Consulting Agreement dated September 1, 2014 among Sports Asylum, Inc. and Jean Arnett.
10.3
  
Consulting Agreement dated September 1, 2014 among Sports Asylum, Inc. and Brad Hargreaves.
10.4
  
Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(6)
10.5
  
First Amendment Agreement dated October 28, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(7)
10.6
  
Convertible Loan Agreement and Note Payable dated November 12, 2014 among Cell MedX Corp., and City Group LLC. (12)
10.7
  
Second Amendment Agreement dated November 13, 2014 to that Technology Purchase Agreement dated October 16, 2014 among Cell MedX Corp., Jean Arnett, and Brad Hargreaves.(8)
10.8
  
Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)
10.9
  
Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves.(9)
10.10
  
First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Jean Arnett.(9)
10.11
  
First Amendment to Stock-Option Agreement dated February 28, 2014 to that Non-Qualified Stock Option Agreement dated November 25, 2014 among Cell MedX Corp. and Brad Hargreaves. (9)
10.12
  
Convertible Loan Agreement and Note Payable dated December 12, 2014 among Cell MedX Corp., and City Group LLC.(10)
10.13
  
Management Consulting Agreement dated January 13, 2015 among Cell MedX Corp., and Dr. John Sanderson, MD.(10)
10.14
  
Stock Option Agreement dated December 12, 2014 among Cell MedX Corp. and Dr. John Sanderson, MD. (10)
10.15
  
Loan Agreement and Note Payable dated April 20, 2015 among Cell MedX Corp., and City Group LLC. (13)
10.16
  
Loan Agreement and Note Payable dated June 17, 2015 among Cell MedX Corp., and City Group LLC. (13)
10.17
  
Loan Agreement and Note Payable dated June 29, 2015 among Cell MedX Corp., and Richard N. Jeffs. (13)
10.18
  
Loan Agreement and Note Payable dated July 7, 2015 among Cell MedX Corp., and City Group LLC. (13)
10.19
  
Loan Agreement and Note Payable dated July 9, 2015 among Cell MedX Corp., and Richard N. Jeffs. (13)
10.20
  
Loan Agreement and Note Payable dated July 15, 2015 among Cell MedX Corp., and Richard N. Jeffs. (13)
10.21
  
Stock Option Agreement dated August 5, 2015 among Cell MedX Corp. and Frank E. McEnulty.(11)
10.22
  
Loan Agreement and Note Payable dated August 12, 2015 among Cell MedX Corp., and Richard N. Jeffs. (13)
10.23
  
Loan Agreement and Note Payable dated September 3, 2015 among Cell MedX Corp., and Richard N. Jeffs. (14)
10.24
  
Consulting Agreement dated September 1, 2015 and effective as of September 23, 2015 among Cell MedX Corp., and Steven H. Bulwa. (14)
10.25
  
Stock Option Agreement dated September 23, 2015 among Cell MedX Corp. and Steven H. Bulwa.(14)
10.26
  
Loan Agreement and Note Payable dated September 24, 2015 among Cell MedX Corp., and City Group LLC. (14)
10.27
  
Loan Agreement and Note Payable dated September 28, 2015 among Cell MedX Corp., and Richard N. Jeffs. (14)
10.28
  
eBalance Prototype Development Agreement dated October 1, 2015 among Cell MedX Corp., and Claudio Tassi. (14)
10.29
  
Non-binding Letter of Intent dated December 4, 2015 to Enter into Development Agreement and License Agreement among Cell MedX Corp., Claudio Tassi, and Bioformed Aesthetic S.L.(15)
10.30
  
Loan Agreement and Note Payable dated November 5, 2015, among Cell MedX Corp., and Tradex Capital Corp.
10.31
  
Loan Agreement and Note Payable dated December 23, 2015, among Cell MedX Corp., and Coventry Capital LLC.(15)
 
 
13
 
10.32
  
Loan Agreement and Note Payable dated February 4, 2016, among Cell MedX Corp., and Tradex Capital Corp.
10.33
  
Loan Agreement and Note Payable dated March 2, 2016, among Cell MedX Corp., and Tradex Capital Corp.
10.34
  
Loan Agreement dated March 3, 2016 between Richard Norman Jeffs and Cell MedX Corp. (16)
10.35
  
Loan Agreement and Note Payable dated March 10, 2016, among Cell MedX Corp., and Tradex Capital Corp. (17)
10.36
  
Loan Agreement and Note Payable dated March 30, 2016, among Cell MedX Corp., and Tradex Capital Corp. (18)
10.37
  
Loan Agreement and Note Payable dated March 31, 2016 among Cell MedX Corp., and Richard N. Jeffs. (18)
10.38
  
Loan Agreement and Note Payable dated April 29, 2016, among Cell MedX Corp., and Richard N. Jeffs. (18)
10.39
  
Loan Agreement and Note Payable dated June 1, 2016, among Cell MedX Corp., and Tradex Capital Corp. (18)
10.40
  
Loan Agreement and Note Payable dated June 2, 2016, among Cell MedX Corp., and Richard N. Jeffs. (18)
10.41
  
Loan Agreement and Note Payable dated June 29, 2016, among Cell MedX Corp., and Tradex Capital Corp. (18)
10.42
  
Loan Agreement and Note Payable dated June 30, 2016, among Cell MedX Corp., and Richard N. Jeffs. (18)
10.43
  
Loan Agreement and Note Payable dated August 8, 2016, among Cell MedX Corp., and Richard N. Jeffs. (18)
10.44
  
Loan Agreement and Note Payable dated August 22, 2016, among Cell MedX Corp., and Tradex Capital Corp. (18)
10.45
  
Letter Agreement dated September 26, 2016, between Jean Arnett, Brad Hargreaves and Cell MedX Corp. (19)
14.1
  
Code of Ethics (3)
     
31.1
  
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
  
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
  
Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2
  
Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101   The following materials from this Quarterly Report on Form 10-Q for the three and six month periods ended November 30, 2016 and 2015 formatted in XBRL (extensible Business Reporting Language):
           (1) Consolidated Balance Sheets at November 30, 2016 (unaudited), and May 31, 2016.
           (2) Unaudited Condensed Interim Consolidated Statements of Operations for the Three and Six Months Ended November 30, 2016 and 2015.
           (3) Unaudited Condensed Interim Consolidated Statement of Stockholders’ Deficit for the Six-month period ended November 30, 2016.
           (4) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the Six months ended November 30, 2016 and 2015.
 
(1)
  
Filed as an exhibit to the Company’s Registration Statement on Form S-1 filed with SEC  on July 13, 2010
(2)
  
Filed as an exhibit to the Company’s Amendment No. 1 to Registration Statement on Form S-1 filed with SEC on October 13, 2010
(3)
  
Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with SEC on August 26, 2014
(4)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on September 5, 2014
(5)
  
Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 9, 2014
(6)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on October 17, 2014
(7)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 3, 2014
(8)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with SEC on November 18 , 2014
(9)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on December 3, 2014
(10)
  
Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 13, 2015
(11)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on August 11, 2015
(12)
  
Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2015
(13)
  
Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 3, 2015
(14)
  
Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on January 14, 2016
(15)
  
Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on October 15, 2015
(16)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on March 9, 2016
(17)
  
Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q filed with the SEC on April 14, 2016
(18)
  
Filed as an exhibit to the Company’s Annual Report on Form 10-K filed with the SEC on September 13, 2016
(19)
  
Filed as an exhibit to the Company’s Current Report on Form 8-K filed with the SEC on September 29, 2016


 
14
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
Cell MedX Corp.
   
Date:
January 17, 2017
By:
/s/ Frank E. McEnulty
   
Frank E. McEnulty
   
President, Chief Executive Officer and Director
   
(Principal Executive Officer)
     
Date:
January 17, 2017
By:
/s/Yanika Silina
   
Yanika Silina
   
Chief Financial Officer
   
(Principal Accounting Officer)
     
 

 
15
 

EX-31.1 2 ex311.htm CERTIFICATION ex311.htm

CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Frank E. McEnulty, certify that:
 
1.   I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2016, of Cell MedX Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:  January 17, 2017


/s/ Frank E. McEnulty   
Frank E. McEnulty
Chief Executive Officer and President
(Principal Executive Officer)

 
 
 

EX-31.2 3 ex312.htm CERTIFICATION ex312.htm


CELL MEDX CORP.
CERTIFICATIONS PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Yanika Silina, certify that:
 
1.   I have reviewed this Quarterly Report on Form 10-Q for the period ending November 30, 2016, of Cell MedX Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.  The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:  January 17, 2017


/s/Yanika Silina   
Yanika Silina
Chief Financial Officer
(Principal Accounting Officer)

 
 
 

EX-32.1 4 ex321.htm CERTIFICATION ex321.htm

 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 

 
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
 
 
(1)   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: January 17, 2017

 
/s/ Frank E. McEnulty
Frank E. McEnulty
Chief Executive Officer and President
(Principal Executive Officer)


 
 
 

EX-32.2 5 ex322.htm CERTIFICATION ex322.htm


 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 
In connection with the Quarterly Report of Cell MedX Corp. (the “Company”) on Form 10-Q for the period ending November 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
 
 
 (1)   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: January 17, 2017
 
 
/s/Yanika Silina   
Yanika Silina
Chief Financial Officer
(Principal Accounting Officer)


 
 
 

EX-101.CAL 6 cmxc-20161130_cal.xml XBRL CALCULATION LINKBASE EX-101.DEF 7 cmxc-20161130_def.xml XBRL DEFINITIONS LINKBASE EX-101.INS 8 cmxc-20161130.xml XBRL INSTANCE LINKBASE 0001493712 2017-01-17 0001493712 2015-05-31 0001493712 2014-06-01 2015-05-31 0001493712 2014-11-25 0001493712 2015-01-13 0001493712 us-gaap:CommonStockMember 2015-05-31 0001493712 CMXC:ObligationToIssueSharesMember 2015-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2015-05-31 0001493712 us-gaap:RetainedEarningsMember 2015-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-05-31 0001493712 2015-08-05 0001493712 2015-08-26 0001493712 CMXC:ShortTermDebtTotal2Member 2016-06-01 2016-11-30 0001493712 2016-05-31 0001493712 2016-06-01 2016-11-30 0001493712 us-gaap:CommonStockMember 2016-05-31 0001493712 CMXC:ObligationToIssueSharesMember 2016-05-31 0001493712 us-gaap:AdditionalPaidInCapitalMember 2016-05-31 0001493712 us-gaap:RetainedEarningsMember 2016-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-05-31 0001493712 us-gaap:ShortTermDebtMember 2015-06-01 2016-05-31 0001493712 CMXC:ShortTermDebt2Member 2015-06-01 2016-05-31 0001493712 CMXC:ShortTermDebt3Member 2015-06-01 2016-05-31 0001493712 CMXC:ShortTermDebt4Member 2015-06-01 2016-05-31 0001493712 CMXC:ShortTermDebtTotalMember 2015-06-01 2016-05-31 0001493712 CMXC:ShortTermDebt5Member 2015-06-01 2016-05-31 0001493712 2016-03-03 0001493712 2017-03-03 0001493712 2018-03-03 0001493712 2019-03-03 0001493712 2020-03-03 0001493712 2015-09-23 0001493712 2016-11-30 0001493712 2015-06-01 2015-11-30 0001493712 2015-11-30 0001493712 us-gaap:CommonStockMember 2015-11-30 0001493712 CMXC:ObligationToIssueSharesMember 2015-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2015-06-01 2015-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2015-11-30 0001493712 us-gaap:RetainedEarningsMember 2015-06-01 2015-11-30 0001493712 us-gaap:RetainedEarningsMember 2015-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-06-01 2015-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2015-12-01 2016-05-31 0001493712 us-gaap:RetainedEarningsMember 2015-12-01 2016-05-31 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-01 2016-05-31 0001493712 2015-12-01 2016-05-31 0001493712 us-gaap:CommonStockMember 2016-06-01 2016-11-30 0001493712 us-gaap:CommonStockMember 2016-11-30 0001493712 CMXC:ObligationToIssueSharesMember 2016-06-01 2016-11-30 0001493712 CMXC:ObligationToIssueSharesMember 2016-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2016-06-01 2016-11-30 0001493712 us-gaap:AdditionalPaidInCapitalMember 2016-11-30 0001493712 us-gaap:RetainedEarningsMember 2016-06-01 2016-11-30 0001493712 us-gaap:RetainedEarningsMember 2016-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-01 2016-11-30 0001493712 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-11-30 0001493712 CMXC:ShortTermDebt7Member 2016-06-01 2016-11-30 0001493712 CMXC:ShortTermDebt8Member 2016-06-01 2016-11-30 0001493712 2015-06-01 2016-05-31 0001493712 2016-09-26 0001493712 2016-10-12 0001493712 2017-10-12 0001493712 2018-10-12 0001493712 2019-10-12 0001493712 2020-10-12 0001493712 CMXC:ShortTermDebt9Member 2016-06-01 2016-11-30 0001493712 CMXC:ShortTermDebt10Member 2016-06-01 2016-11-30 0001493712 2016-09-01 2016-11-30 0001493712 2015-09-01 2015-11-30 0001493712 2016-09-14 0001493712 2016-09-30 0001493712 2017-01-01 2017-01-31 0001493712 2021-10-12 0001493712 2021-03-03 0001493712 us-gaap:WarrantMember 2016-03-04 2021-03-03 0001493712 CMXC:WarrantMember2Member 2016-10-13 2021-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Cell MedX Corp. 0001493712 10-Q 2016-11-30 false --05-31 No No Yes Smaller Reporting Company Q2 2017 40244605 0.001 0.001 300000000 300000000 31000000 40244605 27561 117980 61844 192834 268927 378507 384147 396836 37966 8412 307650 333772 951716 130128 1734498 4048000 -3254597 -4593517 1547 3459 -684066 31000 75000 324629 -1115460 765 -1412552 31000 75000 1734498 -3254597 1547 -501813 -1067078 31000 75000 1448204 -2624502 3220 40245 4048000 -4593517 3459 268927 378507 12358 81663 -29553 -21024 30221 140525 -403305 -163040 -14940 -32838 148754 242000 508938 196200 1258 27561 117980 1543 4599 3715 31000 40245 75000 150747 189710 75607 103252 -1338920 -1509042 -1509042 -630095 -630095 -1338920 -1060101 -479614 1912 2455 1881 469 -1337008 -1506587 -1058220 -479145 33493364 31000000 36014128 31000000 95463 120683 51239 52721 140025 578724 67173 25185 78203 606866 29306 290281 2113 1547 156 870 5704 5649 336 3767 -0.04 -0.05 -0.03 -0.02 797 -94 -274 -37 90419 285 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30,</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30,</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 78%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Management fees incurred to the CEO and President</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,600</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,600</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation&#160;&#160;incurred to the CEO and President (Note 8)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,600</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">446,942</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Management fees incurred to the CFO</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consulting fees incurred to the VP, Corporate Strategy</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,178</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">55,669</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consulting fees incurred to the VP, Technology and Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,178</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,768</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net payments received&#160;&#160;for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(19,301</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Value of options&#160;&#160;issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">496,345</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation&#160;&#160;incurred to the Chief Medical Officer (Note 8)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">66,603</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">159,924</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development costs incurred to a company&#160;&#160;controlled by the Chief Medical Officer</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,700</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,549</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accretion expense associated with a term loan entered into with significant shareholder (Note 7)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,730</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total transactions with related parties</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">175,438</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,286,647</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 66254 89654 95575 98220 56596 59958 81059 81059 3591 4102 180 2897 500959 1502483 241835 474026 36521 6500 -40213 8349 14940 32838 2684 -45800 1681479 880320 1747 1704 6419 3177 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 &#8211; EQUIPMENT</b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Amortization schedule for the equipment at November 30, 2016, and May 31, 2016:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>November 30, 2016</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>May 31, 2016</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 78%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Book value, beginning of the period</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">207,083</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,846</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Changes during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,111</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">201,840</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Amortization</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(36,521</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(20,603</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Book value, end of the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">185,673</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">207,083</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&#160;</p> <p style="margin: 0pt"></p> 207083 185673 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 &#8211; INVENTORY</b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As at November 30, 2016, the inventory consisted of supplies held for resale, and was valued at $3,715 (May 31, 2016 - $4,599). The Company uses lower of cost or net realizable value to determine the book value of the inventory at reporting date.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td colspan="5" style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As at May 31, 2016</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Principal Outstanding</font></td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest Rate</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">per Annum</p></td> <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Accrued</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest / Accretion</p></td> <td style="width: 16%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Total Book</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Value</p></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;$&#160;&#160;&#160;&#160;195,000</font></td> <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;18,588</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;213,588</font></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">490,000</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Non-convertible</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,842</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">502,842</font></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">197,000</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Note 2)</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,620</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">204,620</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Term Loan-</font><font style="font: 7pt Times New Roman, Times, Serif">&#160;</font><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Notes 2 and 7)</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,028</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,028</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">638</font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advances</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">638</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;932,638</font></td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;44,078</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;951,716</font></td></tr> </table> <p style="margin: 0pt"></p> .12 .14 .35 50000 0.06 0.06 0.06 0.06 0.06 0.0 0.06 0.06 0.06 0 Convertible Non-Convertible Related party(Note 2) Related Party Term Loan (Notes 2 and 7) Advances Non-Convertible Related Party(Note 2) Term Loan - Related Party (Notes 2 and 7) Advances 20452 18588 12842 7620 5028 44078 1031 663 18758 130128 213588 502842 204620 30028 951716 638 50182 32958 43758 3230 134676 195000 490000 197000 50000 932638 638 49151 32295 50000 3230 29684 71139 13730 7473 2979 20991 11085 5596 6458 36521 6500 18510 2587 -4264 -8190 20991 11085 496345 -2979 78203 606866 606866 261294 261294 78203 1912 2455 2455 -1673 -1673 1912 496345 496345 20364 20364 25000 25000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 - ORGANIZATION</b>&#160;<b>AND NATURE OF OPERATIONS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Cell MedX Corp. (the &#8220;Company&#8221;) was incorporated under the laws of the State of Nevada. On November 26, 2014, the Company formed a subsidiary, Avyonce Cosmedics Inc., (&#8220;Avyonce&#8221;) and on April 26, 2016, the Company formed an additional subsidiary, Cell MedX (Canada) Corp. (&#8220;Cell MedX Canada&#8221;). Both subsidiaries were formed under the laws of British Columbia.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company is an early development stage company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson&#8217;s disease, and high blood pressure.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Unaudited Interim Financial Statements</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2016, included in the Company&#8217;s Annual Report on Form 10-K, filed with the SEC. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six month periods ended November 30, 2016, are not necessarily indicative of the results that may be expected for the year ending May 31, 2017.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Reclassifications</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Certain prior period amounts in the accompanying unaudited consolidated interim financial statements have been reclassified to conform to the current period&#8217;s presentation. &#160;These reclassifications had no net effect on the consolidated results of operations or financial position for any period presented.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Going Concern</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The accompanying unaudited consolidated interim financial statements have been prepared assuming the Company will continue as a going concern. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations. &#160;The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern. &#160;These unaudited interim consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. &#160;Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;2&#8211; RELATED PARTY TRANSACTIONS</b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Amounts due to related parties, other than notes payable to related parties (Notes 6 and 7) at November 30, 2016, and May 31, 2016:</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>November 30, </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>May 31, </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 78%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Chief Executive Officer (&#8220;CEO&#8221;) and President</font></td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">89,654</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">66,254</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Vice President (&#8220;VP&#8221;), Corporate Strategy</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">98,220</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">95,575</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the VP, Technology and Operations</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">59,958</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">56,596</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Chief Medical Officer</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">81,059</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">81,059</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to a company owned by VP,&#160;&#160;Corporate Strategy&#160;&#160;and VP Technology and Operations</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,704</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,747</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Chief Financial Officer (&#8220;CFO&#8221;)</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,177</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,419</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to related parties</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">333,772</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">307,650</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Amounts are unsecured, due on demand and bear no interest.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">During the six months ended November 30, 2016 and 2015, the Company had the following transactions with related parties:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30,</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30,</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2015</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 78%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Management fees incurred to the CEO and President</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,600</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">21,600</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation&#160;&#160;incurred to the CEO and President (Note 8)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,600</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">446,942</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Management fees incurred to the CFO</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consulting fees incurred to the VP, Corporate Strategy</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,178</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">55,669</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consulting fees incurred to the VP, Technology and Operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,178</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,768</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net payments received&#160;&#160;for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(19,301</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Value of options&#160;&#160;issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">496,345</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation&#160;&#160;incurred to the Chief Medical Officer (Note 8)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">66,603</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">159,924</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development costs incurred to a company&#160;&#160;controlled by the Chief Medical Officer</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,700</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,549</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Accretion expense associated with a term loan entered into with significant shareholder (Note 7)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">13,730</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Total transactions with related parties</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">175,438</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,286,647</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On September 26, 2016, the Company entered into a letter agreement (the &#8220;Letter Agreement&#8221;) with Jean Arnett and Brad Hargreaves to cancel the unvested portion of the options granted to Ms. Arnett and Mr. Hargreaves by the Company (Note 8). In addition, the Company renegotiated its consulting arrangements with Ms. Arnett and Mr. Hargreaves. Based on the Letter Agreement, the Company has agreed to pay each of Ms. Arnett and Mr. Hargreaves CAD$5,000 per month, beginning effective August 1, 2016, for duration of six months.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>November 30, </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>May 31, </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 78%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Chief Executive Officer (&#8220;CEO&#8221;) and President</font></td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">89,654</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">66,254</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Vice President (&#8220;VP&#8221;), Corporate Strategy</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">98,220</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">95,575</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the VP, Technology and Operations</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">59,958</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">56,596</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Chief Medical Officer</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">81,059</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">81,059</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to a company owned by VP,&#160;&#160;Corporate Strategy&#160;&#160;and VP Technology and Operations</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,704</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,747</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to the Chief Financial Officer (&#8220;CFO&#8221;)</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,177</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,419</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Due to related parties</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">333,772</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">307,650</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>November 30, 2016</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>May 31, 2016</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 78%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Book value, beginning of the period</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">207,083</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 8%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,846</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Changes during the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,111</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">201,840</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Amortization</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(36,521</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(20,603</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Book value, end of the period</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">185,673</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">207,083</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 4599 3715 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;6 &#8211; NOTES AND ADVANCES PAYABLE</b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The tables below summarize the short-term loans and advances outstanding as at November 30, 2016, and May 31, 2016:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td colspan="5" style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As at November 30, 2016</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Principal Outstanding</font></td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest Rate</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">per Annum</p></td> <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Accrued</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest / Accretion</p></td> <td style="width: 16%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Total Book</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Value</p></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160; 49,151</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Non-convertible</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,031</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 50,182</font></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">32,295</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Note 2)</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">663</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">32,958</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Term Loan-</font><font style="font: 7pt Times New Roman, Times, Serif">&#160;</font><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Notes 2 and 7)</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">18,758</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,758</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,230</font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advances</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,230</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;134,676</font></td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,452</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;130,128</font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td colspan="5" style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As at May 31, 2016</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Principal Outstanding</font></td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest Rate</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">per Annum</p></td> <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Accrued</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest / Accretion</p></td> <td style="width: 16%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Total Book</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Value</p></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;$&#160;&#160;&#160;&#160;195,000</font></td> <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Convertible</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;18,588</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;213,588</font></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">490,000</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Non-convertible</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">12,842</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">502,842</font></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">197,000</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Note 2)</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,620</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">204,620</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Term Loan-</font><font style="font: 7pt Times New Roman, Times, Serif">&#160;</font><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Notes 2 and 7)</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,028</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">30,028</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">638</font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advances</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">638</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;932,638</font></td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;44,078</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;951,716</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">During the six-month period ended November 30, 2016, the Company entered into a number of loan agreements for $75,000 (May 31, 2016 - $480,000). These loans bare interest at 6% per annum, are unsecured and payable on demand. During the same period, the Company entered into a number of loan agreements with Mr. Richard Jeffs (&#8220;Mr. Jeffs&#8221;), a major shareholder, for a total of $73,754 (CAD$96,500) (May 31, 2016 &#8211; $247,000). The loans of CAD$96,500 bear interest at 6% per annum, are unsecured and are payable on demand.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On September 30, 2016, Mr. Jeffs notified the Company that he had assigned all rights to his claims against the Company in the amount of $250,000 to two unaffiliated parties. The assignees notified the Company of their intention to convert the debt acquired by them from Mr. Jeffs into the units of the Company&#8217;s common stock as part of the non-brokered private placement offering (the &#8220;Offering&#8221;), which the Company closed on October 12, 2016 (Note 8).</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On October 12, 2016, as part of its Offering, the Company settled a total of $1,006,691 owed under the notes payable (the &#8220;Debt&#8221;), which consisted of $949,001 in principal and $57,690 in accrued interest. The Debt was converted to 6,711,272 units of&#160;the Company's&#160;common stock at $0.15 per unit. Each unit consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year. The Company recorded a loss on settlement of $805,353, which resulted from the difference between the fair market value of the stock at the date of the conversion being $0.27 per share, and price of the unit offered as part of the private placement being $0.15 per unit.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As of November 30, 2016, the Company recorded $20,991 (2015 - $11,085) in interest expense associated with above loans.</p> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td colspan="5" style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>As at November 30, 2016</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="width: 15%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Principal Outstanding</font></td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest Rate</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">per Annum</p></td> <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">&#160;</td> <td style="width: 15%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Accrued</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Interest / Accretion</p></td> <td style="width: 16%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Total Book</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Value</p></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160; 49,151</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Non-convertible</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 1,031</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160; 50,182</font></td></tr> <tr> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">32,295</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Note 2)</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">663</font></td> <td style="vertical-align: top; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">32,958</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6%</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Term Loan-</font><font style="font: 7pt Times New Roman, Times, Serif">&#160;</font><font style="font: 10pt Times New Roman, Times, Serif">Related Party (Notes 2 and 7)</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">18,758</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">43,758</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,230</font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0%</font></td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Advances</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,230</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;134,676</font></td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;20,452</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$&#160;&#160;&#160;&#160;&#160;&#160;130,128</font></td></tr> </table> <p style="margin: 0pt"></p> 75000 480000 .06 0.06 0.06 73754 247000 96500 20991 11085 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 &#8211; TERM LOAN</b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On March 3, 2016, the Company entered into a loan agreement (the &#8220;Term Loan Agreement&#8221;) with Mr. Jeffs for a loan in the principal amount of $50,000 maturing March 3, 2017, with interest payable at a rate of 6% per annum (the &#8220;Term Loan&#8221;).&#160;&#160;As additional consideration for the Term Loan, the Company issued to Mr. Jeffs share purchase warrants (the &#8220;Warrants&#8221;) for the purchase of up to 2,000,000 shares of the Company&#8217;s common stock, exercisable for a period of five years at a price of $0.15 per share if exercised during the first year, $0.25 per share if exercised during the second year, $0.40 per share if exercised during the third year, $0.60 per share if exercised during the fourth year and $0.75 per share during the fifth year. The Warrants were determined to be detachable from the debt instrument, as the debt instrument does not have to be surrendered to exercise the warrant. Under the guidance provided by ASC 470-20-25-2, proceeds from the sale of debt instrument with stock purchase warrants must be allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the warrants was $25,000 and was recorded to additional paid-in capital.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Term Loan has effective interest rate of 77.51%, which was due primarily to the recording of non-cash accretion interest. During the six-month period ended November 30, 2016, the Company recognized accretion expense of $13,730 (2015 - $Nil).</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">At March 3, 2016, the fair value of Warrants was valued using the Black-Scholes Option pricing model using the following assumptions:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 63%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="vertical-align: bottom; width: 37%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>At March 3, 2016</b></font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Warrant Life</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.33%</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">16%</font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="margin: 0pt"></p> <p style="margin: 0pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 63%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="vertical-align: bottom; width: 37%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>At March 3, 2016</b></font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Warrant Life</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.33%</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">16%</font></td></tr> </table> <p style="margin: 0pt"></p> 0.0133 0.16 2000000 5 .15 .25 .40 .60 .75 77.51 13730 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;8 &#8211; SHARE CAPITAL</b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In January 2015 the Company received a subscription to 150,000 units (each a &#8220;Unit&#8221;) at a price of $0.50 per Unit for total proceeds of $75,000. Each Unit consisted of one share of the Company&#8217;s common stock and one warrant for the purchase of one additional share of the Company&#8217;s common stock, exercisable at a price of $1.00 per share, expiring on December 31, 2015. The Company issued the shares on September 20, 2016. Since the expiration date of the warrants had passed, the warrants were not issued.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On October 12, 2016, the Company closed its Offering at a price of $0.15 per unit, by issuing 2,383,333&#160;units for cash proceeds of $357,500 and 6,711,272 units to the holders of the Company&#8217;s notes payable (Note 6) for debt settlement of $1,006,691. Each unit sold under the Offering consisted of one common share of the Company and one share purchase warrant expiring on October 12, 2021, and entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b><u>Options</u></b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On November 25, 2014, as part of the technology purchase agreement dated for reference October 16, 2014, and as amended on October 28, 2014 and November 13, 2014, the Company issued to the vendors of the Technology (the &#8220;Vendors&#8221;) options for the purchase of up to 20,000,000 shares of the Company&#8217;s common stock at an initial exercise price of $0.05 per share and expiring on the 5th year anniversary of the applicable vesting date, or on December 31, 2019, for those options that have not vested.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On August 26, 2015, the board of directors of the Company determined that the options to purchase up to 2,500,000 common shares of the Company&#8217;s common stock granted to the Vendors for the Technology, which were to vest upon the design and commencement of the first clinical trial, have vested. The total fair value of the vested options was calculated to be $496,345 (Note 2) and was determined using the Black-Scholes Option pricing model at the grant date using the following assumptions:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 61%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>At August 26, 2015</b></font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Life of Options</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.49%</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">216%</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On September 26, 2016, the Company entered into a letter agreement with the Vendors to cancel remaining 17,500,000 options (Note 2).</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On January 13, 2015, the Company issued 2,400,000 non-transferrable options to its Chief Medical Officer. The options are exercisable at $0.67 per share and vest quarterly starting on March 31, 2015, in equal portions of 200,000 shares per vesting period, and expire on the 5th year anniversary of the applicable vesting date.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The total fair value of the options was calculated to be $591,503 and was determined using the Black-Scholes Option pricing model at the grant date using the following assumptions:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 61%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>At January 13, 2015</b></font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Life of Options</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years from vesting</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.37%</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27%</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><br /> As of November 30, 2016, options to acquire up to 1,400,000 shares of the Company&#8217;s common stock have vested, and the Company recognized $66,603 (2015 - $159,924) (Note 2) as stock-based compensation expense for the six-month period ended November 30, 2016. Further $58,197 will be recognized in the future periods.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On August 5, 2015, the Company issued to its CEO, President and a member of the board of directors options to purchase up to 2,500,000 shares of the Company&#8217;s common stock (the &#8220;CEO Options&#8221;). The CEO Options are exercisable at $0.35 per share. As of November 30, 2016, all CEO Options have vested.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The CEO Options expire on the 5th year anniversary of the particular vesting date, subject to certain early termination provisions, upon the death of the optionee, or if the optionee ceases to act for the Company in any capacity either voluntarily or as a result of a termination or removal for cause.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The total fair value of the options was calculated to be $616,886 and was determined using the Black-Scholes option pricing model at the grant date using the following assumptions:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 61%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 39%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>At August 5, 2015</b></font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Life of Options</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years from vesting</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.65%</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">218%</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><br /> During the six-month period ended November 30, 2016, the Company recognized $11,600 as share-based compensation expense (2015 - $446,942) (Note 2).</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The changes in the number of stock options outstanding during the six-month period ended November 30, 2016, and for the year ended May 31, 2016, are as follows:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30, 2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>May 31, 2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of options</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average exercise price</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of options</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average exercise price</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding, beginning</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,050,000</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.14</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,400,000</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.12</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,650,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.34</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options cancelled</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(17,500,000</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.05</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding, ending</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,550,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.35</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,050,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.14</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable, ending</font></td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,550,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,650,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Details of options outstanding and exercisable as at November 30, 2016, are as follows:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise price</b></font></td> <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Grant date</b></font></td> <td style="width: 24%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of options</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>granted</b></p></td> <td style="width: 25%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of options</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercisable</b></p></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.05</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">November 25, 2014</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.67</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 13, 2015</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,400,000</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,400,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.35</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 5, 2015</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.20</font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 23, 2015</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,550,000</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,550,000</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><br /> At November 30, 2016, the weighted average remaining contractual life of the stock options outstanding and exercisable was 3.89 years.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Warrants</b></font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On March 3, 2016, the Company issued non-transferrable share purchase warrants to acquire up to 2,000,000 shares of the Company&#8217;s common stock expiring on March 3, 2021, to Mr. Jeffs as additional consideration for the Term Loan (Note 7). The exercise price of these warrants is as follows:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 61%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Period expiring on:</b></font></td> <td style="vertical-align: bottom; width: 39%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2017</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.15</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2018</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.25</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2019</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.40</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2020</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.60</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2021</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.75</font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On October 12, 2016, as part of the Offering, the Company issued warrants to acquire up to 9,094,605 of the Company&#8217;s common stock expiring on October 12, 2021. The exercise price of these warrants is as follows:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 61%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Period expiring on:</b></font></td> <td style="vertical-align: bottom; width: 39%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2017</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.50</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2018</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.75</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2019</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$1.00</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2020</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$1.25</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2021</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$1.50</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The changes in the number of warrants outstanding during the six-month period ended November 30, 2016, and for the year ended May 31, 2016, are as follows:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 55%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 26%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30, 2016</b></p></td> <td style="width: 19%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>May 31, 2016</b></p></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding, beginning</font></td> <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,094,605</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding, ending</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,094,605</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Details of warrants outstanding as at November 30, 2016, are as follows:</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 55%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise price</b></font></td> <td style="width: 23%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Expiry Date</b></font></td> <td style="width: 22%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of warrants</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercisable</b></p></td></tr> <tr> <td style="vertical-align: bottom"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$0.15 1st year; $0.25 2nd year; $0.40 3rd year;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$0.60 4th year; $0.75 5th year</p></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2021</font></td> <td style="vertical-align: top; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,000,000</font></td></tr> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$0.50 1st year; $0.75 2nd year; $1.00 3rd year</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$1.25 4th year; $1.50 5th year</p></td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2021</font></td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">9,094,605</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,094,605</font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">At November 30, 2016, the weighted average remaining contractual life of the share purchase warrants was 4.76 years.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%">&#160;</td> <td nowrap="nowrap" style="font-weight: bold; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>At August 26, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Life of Options</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.49% </font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">216%</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%">&#160;</td> <td nowrap="nowrap" style="font-weight: bold; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; font-weight: bold; line-height: 107%; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif"><b>At January 13, 2015</b></font></td> <td nowrap="nowrap" style="font-weight: bold; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Life of Options</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years from vesting</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#160; 1.37%</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil&#160; </font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">27%</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>At August 5, </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><b>2015</b></p></td> <td nowrap="nowrap" style="line-height: 107%; text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Life of Options</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5 years from vesting </font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-Free Interest Rate</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.65%&#160;</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Dividend Yield</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Nil</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Expected Stock Price Volatility</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">218%</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30, 2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>May 31, 2016</b></p></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of options</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average exercise price</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Number of options</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Weighted average exercise price</b></font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding, beginning</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,050,000</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.14</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">22,400,000</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: right; line-height: 107%">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.12</font></td> <td nowrap="nowrap" style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options granted</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,650,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.34</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options cancelled</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(17,500,000</font></td> <td nowrap="nowrap" style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.05</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding, ending</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,550,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.35</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,050,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.14</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable, ending</font></td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,550,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.30</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,650,000</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.27</font></td> <td nowrap="nowrap" style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 27%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise price</b></font></td> <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Grant date</b></font></td> <td style="width: 24%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of options</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>granted</b></p></td> <td style="width: 25%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of options</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercisable</b></p></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.05</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">November 25, 2014</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.67</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">January 13, 2015</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,400,000</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,400,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.35</font></td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">August 5, 2015</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,500,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.20</font></td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">September 23, 2015</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">150,000</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">7,550,000</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">6,550,000</font></td></tr> </table> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 61%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Period expiring on:</b></font></td> <td style="vertical-align: bottom; width: 39%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2017</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.15</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2018</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.25</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2019</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.40</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2020</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.60</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2021</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.75</font></td></tr> </table> P5Y 0.0149 2.16 0.0137 0.27 P5Y 0.0165 2.18 P5Y 22400000 7550000 2650000 2500000 1400000 2500000 150000 6550000 .34 .27 .30 0.05 0.67 0.35 0.20 2500000 2400000 2500000 150000 <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>NOTE&#160;9 &#8211; SUBSEQUENT EVENTS</b></font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">a)&#160;&#160;</font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif">Subsequent to November 30, 2016, the Company received 20 eBalance Pro wellness devices.&#160;&#160;The Company paid the developer $93,764 (EURO 86,776) for the devices.&#160;&#160;</font></td></tr> </table> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">b)&#160;&#160;</font></td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif">In January 2017 the Company received CAD$40,000 under loan agreements with a non-related party, and CAD$15,000 under a loan agreement with Mr. Richard Jeffs. The loans bear interest at 6% per annum, are unsecured and payable on demand (Note 6).</font></td></tr> </table> <p style="margin: 0pt"></p> 150000 0.50 75000 Each Unit consists of one share of the Company's common stock and one warrant for the purchase of one additional share of the Company's common stock, exercisable at a price of $1.00 per share, expiring one year after the issuance of the Units. P5Y 19301 31000000 31000000 31000000 40244605 21600 21600 11600 446942 6000 6000 25178 55669 25178 43768 -19301 496345 50000 66603 159924 25700 5549 13730 175438 1286647 25846 207083 20603 36521 201840 15111 96500 17500000 5000 6 0.15 2383333 357500 6711272 1006691 .5 .75 1 1.25 1.5 20000000 0.05 2500000 496345 2400000 0.67 200000 1400000 591503 58197 66603 159924 2500000 .35 616886 11600 446942 P3Y10M 2000000 9094605 P4Y9M 11172 -805353 -805353 20364 805353 11471 6592 357500 357500 2383 355117 2383333 1812044 6712 1805332 6711272 150 -75000 74850 150000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 &#8211; UNEARNED REVENUE</b></p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On September 14, 2016, the Company received a $11,172 (CAD$15,000) deposit.</p> <p style="font: 12pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="margin: 0pt"></p> 11172 15000 250000 949001 57690 805353 0.27 Each unit consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year. <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: top; width: 61%; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Period expiring on:</b></font></td> <td style="vertical-align: bottom; width: 39%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise Price</b></font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2017</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.50</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2018</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$0.75</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2019</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$1.00</font></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2020</font></td> <td style="vertical-align: bottom; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$1.25</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2021</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$1.50</font></td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 55%; border-bottom: black 1.5pt solid; font: 11pt/107% Calibri, Helvetica, Sans-Serif"><font style="font: 10pt Times New Roman, Times, Serif"><b>Exercise price</b></font></td> <td style="width: 23%; border-bottom: black 1.5pt solid; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif"><b>Expiry Date</b></font></td> <td style="width: 22%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Number of warrants</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>exercisable</b></p></td></tr> <tr> <td style="vertical-align: bottom"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$0.15 1st year; $0.25 2nd year; $0.40 3rd year;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$0.60 4th year; $0.75 5th year</p></td> <td style="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">March 3, 2021</font></td> <td style="vertical-align: top; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2,000,000</font></td></tr> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$0.50 1st year; $0.75 2nd year; $1.00 3rd year</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">$1.25 4th year; $1.50 5th year</p></td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">October 12, 2021</font></td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">9,094,605</font></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 2.25pt double; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&#160;</td> <td style="border-bottom: black 2.25pt double; font: 11pt/107% Calibri, Helvetica, Sans-Serif">&#160;</td> <td style="border-bottom: black 2.25pt double; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">11,094,605</font></td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 55%; border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="width: 26%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six months ended</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>November 30, 2016</b></p></td> <td style="width: 19%; border-bottom: black 1.5pt solid"> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><b>May 31, 2016</b></p></td></tr> <tr> <td style="vertical-align: top; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding, beginning</font></td> <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="vertical-align: bottom; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,094,605</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td></tr> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding, ending</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">11,094,605</font></td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td></tr> </table> 17500000 0.05 .5 .75 1 1.25 1.5 20 93764 86776 40000 15000 .06 11094605 11094605 $0.15 1st year; $0.25 2nd year; $0.40 3rd year; $0.60 4th year; $0.75 5th year $0.50 1st year; $0.75 2nd year; $1.00 3rd year; $1.25 4th year; $1.50 5th year 11094605 2000000 9094605 2021-03-03 2021-10-12 EX-101.LAB 9 cmxc-20161130_lab.xml XBRL LABELS LINKBASE Common Stock Equity Components [Axis] Obligation to Issue Shares Additional Paid-In Capital Deficit Accumulated Accumulated Other Comprehensive Income Short Term Borrowing Total Short-term Debt, Type [Axis] Short term borrowing 1 Short term borrowing 2 Short term borrowing 3 Short Term Borrowing 4 Short Term Borrowing Total Short Term Borrowing 5 Short Term Borrowing 2 Short Term Borrowing 3 Short Term Borrowing 4 Short Term Borrowing 5 Terms of Warrant Class of Warrant or Right [Axis] Terms of Warrant Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets Cash Inventory Other current assets Total current assets Equipment Total assets LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable Accrued liabilities Due to related parties Notes and advances payable Unearned revenue Total liabilities STOCKHOLDERS' DEFICIT Common stock, $0.001 par value, 300,000,000 shares authorized; 40,244,605 and 31,000,000 shares issued and outstanding at November 30, 2016 and May 31, 2016, respectively Additional paid-in capital Obligation to issue shares Accumulated deficit Accumulated other comprehensive income Total stockholders deficit Total liabilities and stockholders deficit Common stock, par value Common stock, shares authorized Common stock, shares issued Income Statement [Abstract] Revenue Sales Cost of goods sold Gross margin Operating expenses Amortization Consulting fees General and administrative expenses Research and development costs Stock-based compensation Total operating expenses Other items Accretion expense Gain on sale of equipment Interest Loss on settlement of debt Net loss Unrealized foreign exchange translation gain Comprehensive loss Net loss per common share, basic and diluted Weighted average number of shares outstanding, basic and diluted Statement [Table] Statement [Line Items] Beginning balance, amount Beginning balance, in shares Shares issued for cash, amount Shares issued for cash, shares Shares issued for debt, amount Shares issued for debt, shares Issuance of shares subscribed, amount Issuance of shares subscribed, shares Stock-based compensation Options issued for technology Options issued for consulting fees Warrants issued for term loan Net loss for the period Translation to reporting currency Ending balance, amount Ending balance, in shares Statement of Cash Flows [Abstract] Cash flows used in operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Accretion expense Accrued interest on notes payable Amortization Consulting fees - non-cash Foreign exchange gain Gain on sale of equipment Loss on settlement of debt Research and development costs - non-cash Changes in operating assets and liabilities: Inventory Other current assets Accounts payable Accrued liabilities Unearned revenue Due to related parties Net cash flows used in operating activities Cash flows used in investing activities: Acquisition of equipment Net cash used in investing activities Cash flows from financing activities: Advances payable Proceeds from notes payable Proceeds from subscription to shares Net cash provided by financing activities Effects of foreign currency exchange on cash Increase in cash Cash, beginning Cash, ending Non-cash investing transactions: Sale of equipment recorded as settlement of due to related parties Organization, Consolidation and Presentation of Financial Statements [Abstract] Note 1 - Organization and Nature of Operations Related Party Transactions [Abstract] Note 2 - Related Party Transactions Property, Plant and Equipment [Abstract] Note 3 - Equipment Inventory Disclosure [Abstract] Note 4 - Inventory Notes to Financial Statements Note 5 - Unearned Revenue Debt Disclosure [Abstract] Note 6 - Notes and Advances Payable Note 7 - Term Loan Equity [Abstract] Note 8- Share Capital Subsequent Events [Abstract] Note 9 - Subsequent Events Schedule of Amounts Due To Related Parties Schedule of Related Party Transactions Amortization schedule, equipment Schedule of short term loans and advances, November 30, 2016 Schedule of short term loans and advances, May 31, 2016 Assumptions, Fair value of warrants Schedule of Fair Value of Options Granted and Assumptions August 26, 2015 Schedule of Fair Value of Options Granted and Assumptions January 13, 2015 Schedule of Fair Value of Options Granted and Assumptions August 5, 2015 Schedule of Changes in Stock Options Schedule of Outstanding Options Schedule of Warrant expiration dates, March 3, 2016 issuance Schedule of Warrant expiration dates, October 12, 2016 issuance Schedule of changes in Warrants Schedule of Warrants outstanding Due to the Chief Executive Officer (CEO) and President Due to the Vice President (VP), Corporate Strategy Due to the VP, Technology and Operations Due to the Chief Medical Officer Due to a company owned by VP, Corporate Strategy and VP Technology and Operations Due to the Chief Financial Officer (CFO) Due to related parties Management fees incurred to the CEO and President Stock-based compensation incurred to the CEO and President (Note 8) Management fees incurred to the CFO Consulting fees incurred to the VP, Corporate Strategy Consulting fees incurred to the VP, Technology and Operations Net payments received for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy Value of options issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8) Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs Stock-based compensation incurred to the Chief Medical Officer (Note 8) Research and development costs incurred to a company controlled by the Chief Medical Officer Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6) Accretion expense associated with a term loan entered into with significant shareholder (Note 7) Total transactions with related parties Transactions with Jean Arnett and Brad Hargreaves Monthly consulting fee, Canadian Dollars Term of renegotiated consulting fee commencing August 1, 2016, in months Book value, beginning of the period Changes during the period Amortization Book value, end of the period Inventory, supplies for resale Deposit received Deposit received (CDN dollar equivalent) Principal Outstanding Interest Rate per Annum Additional Description Accrued Interest Total As at May 31, 2016 Notes and advances Loans, unrelated parties Interest rate Loans, Richard Jeffs, major shareholder, total (USD) Loans, Richard Jeffs, major shareholder, total (CAD) Loans, Richard Jeffs, due on demand, (CAD) Interest rate Interest expense Transactions with Richard Jeffs Amount of assignment of debt to third parties Non-brokered Private Placement Offering and debt settlement Price Per Unit Units Issued to Holders of Notes payable Debt Settlement proceeds Principal converted to shares Accrued interest converted to shares Terms of Units Exercise Price, Share purchase warrants Loss on debt settlement Fair market value of common stock on date of debt conversion Assumptions used in warrant valuation Expected Warrant Life Risk-Free Interest Rate Expected Dividend Yield Expected Stock Price Volatility Loan agreement - March 3, 2016 Loan proceeds Interest rate Share purchase warrants issued as consideration Term of warrants, years Exercise price, warrants Effective interest rate Accretion Expense Option Valuation Assumptions Expected Life of Options Risk-Free Interest Rate Expected Dividend Yield Expected Stock Price Volatility Expected Life of Options Risk-Free Interest Rate Expected Dividend Yield Expected Stock Price Volatility Expected Life of Options Risk-Free Interest Rate Expected Dividend Yield Expected Stock Price Volatility Stock Option Activity Options outstanding, beginning Options granted Options cancelled Options outstanding, ending Options exercisable, ending Weighted Average Exercise Price Options outstanding, beginning Options granted Options cancelled Options outstanding, ending Options exercisable, ending Details of Options Outstanding Exercise Price Number of Options Granted Number of Options Exercisable Total Options granted Exercise price, warrants Warrant Activity Warrants outstanding, beginning Warrants issued Warrants outstanding, ending Details of Warrants Oustanding Exercise Price Number of warrants exerciseable Warrant expiry date Transactions during January 2015 Subscription units Price per Unit Proceeds from subscription Terms of Units Units Issued Total Proceeds Options Issued - November 25, 2014 Stock option issued Exercise Price per Share Options Vested Total Fair Value Option Vested Unvested stock options canceled Options Issued - January 13, 2015 - CMO Stock Option Issued Exercise Price per Share Share which vest each quarter Total fair value options granted Options Vested at report date Stock based compensation expense recognized in period Stock based compensation expense recognized in future periods Options Issued August 5, 2015 - CEO Stock Option Issued Exercise Price per Share Total fair value options granted Stock based compensation expense recognized in period Weighted average remaining contractual life, oustanding stock options at report date Warrants Share purchase warrants granted Remaining contractual life Number of eBalance Pro wellness devices received Payment to developer for devices Payment to developer for devices, EUROS Proceeds from Loan Agreements, CAD, unrelated party Proceeds from Loan Agreement, CAD, Jeffs Interest rate on loans Consulting fees incurred, Vice President Corporate Strategy Consulting fees incurred, Vice President Technology and Operations Due to CEO Amounts due and payable to CFO Due to Chief Medical Officer Amounts due and payable to Company owned by VP Corporate Strategy and VP Technology Due to Vice President Corporate Strategy Due to Vice President Technology and Operations Equipment acquired from VP Technology and VP Corporate Strategy, amount The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Management fees incurred, CEO and President Management fees incurred, CFO Obligation to issue shares, Obligation to Issue Shares, Member Property, Plant and Equipment, Amortization, Table Text Block Research and development charges incurred by Chief Medical Officer Granted Stock Options, weighted average exercise price Stock options, grants in period Short Term Debt Short Term Debt Short Term Debt, Total, Member Stock-based compensation incurred, Chief Medical Officer Total Short Term Debt, including Interest Total Transactions, related parties Unrealized foreign currency exchange gain Share based compensation, Options issued, value Share based compensation, options issued to consultants Short Term Debt, Short term Borrowings Short Term Debt, Short term Borrowings Short Term Debt, Short term Borrowings Short Term Debt, Short term Borrowings Short Term Debt, Short term Borrowings, TOTAL Share purchase warrants issued as consideration Term of share purchase warrants in years Share based compensation, stock options, valuation assumptions Share based compensation, stock options, valuation assumptions Share based compensation, fair value assumption, risk free interest rate, options granted Share based compensation, fair value assumption, expected volatiliy, options granted Share based compensation, expected dividend rate, options granted Share based compensation, fair value assumption, expected term, options granted Share based compensation, fair value assumption, risk free interest rate, options granted Share based compensation, fair value assumption, expected volatiliy, options granted Share based compensation, expected dividend rate, options granted Share based compensation, fair value assumption, expected term, options granted Share based compensation, fair value assumption, risk free interest rate, options granted Share based compensation, fair value assumption, expected volatiliy, options granted Share based compensation, expected dividend rate, options granted Number of shares vesting each quarter under stock option plan, Consultant Additions (reductions) to property and equipment ShortTermDebtTotalMember ShortTermDebt9Member ShortTermDebt10Member WarrantMember2Member Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Costs and Expenses Interest Expense Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding Stock Granted, Value, Share-based Compensation, Gross Amortization [Default Label] GainOnSaleOfEquipmentCF GainsLossesOnExtinguishmentOfDebtCF Increase (Decrease) in Inventories Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Recognition of Deferred Revenue Increase (Decrease) in Due to Related Parties Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) Cash Equivalents, at Carrying Value Cash and Cash Equivalents, at Carrying Value TotalTransactionsRelatedParties Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment DebtInstrumentInterestRateEffectivePercentage2 Debt Instrument, Interest Rate During Period ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1a ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1a2 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate2 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate2 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm3 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1a3 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate3 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate3 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2 Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ExercisePricesWarrants TermsOfSubscriptionUnits ExercisePriceStockOptionJan2015 StockOptionIssuedAugust2015 ExercisePriceStockOptionAugust2015 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValueCEO ShareBasedCompensationInPeriodAug2015Option ShortTermDebt6Member EX-101.PRE 10 cmxc-20161130_pre.xml XBRL PRESENTATION LINKBASE EX-101.SCH 11 cmxc-20161130.xsd XBRL SCHEMA LINKBASE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Shareholders Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 1 - Organization and Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 2 - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 3 - Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 4 - Inventory link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 5 - Unearned Revenue link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 6 - Notes and Advances Payable link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 7 - Term Loan link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 8 - Share Capital link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 9 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 2 - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 3 - Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 6 - Notes and Advances Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note 7 - Term Loan (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Note 8 - Share Capital (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Note 2 - Related Party Transactions - Schedule of Amounts Due To Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Note 2 - Related Party Transactions - Schedule of Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Note 2 - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note 3 - Equipment - Amortization schedule, equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Note 4 - Inventory (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Note 5 - Unearned Revenue (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, November 30, 2016 (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, May 31, 2016 (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Note 6 - Notes and Advances Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Note 7 - Term Loan - Assumptions, Fair value of warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Note 7 - Term Loan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 26, 2015 (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions January 13, 2015 (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 5, 2015 (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Note 8 - Share Capital - Schedule of Changes in Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Note 8 - Share Capital - Schedule of Outstanding Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Note 8 - Share Capital - Schedule of Warrant Exercise Prices March 2016 (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Note 8 - Share Capital - Schedule of Warrant Exercise Prices October 2016 (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Note 8 - Share Capital - Schedule of Changes in Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Note 8 - Share Capital - Schedule of Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Note 8 - Share Capital (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Note 9 - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink XML 12 R1.htm IDEA: XBRL DOCUMENT v3.6.0.2
Document and Entity Information - shares
 6 Months Ended
Nov. 30, 2016
Jan. 17, 2017
Document And Entity Information    
Entity Registrant Name Cell MedX Corp.  
Entity Central Index Key 0001493712  
Document Type 10-Q  
Document Period End Date Nov. 30, 2016  
Amendment Flag false  
Current Fiscal Year End Date --05-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   40,244,605
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2017  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Balance Sheets (Unaudited) - USD ($)
Nov. 30, 2016
May 31, 2016
Current assets    
Cash $ 117,980 $ 27,561
Inventory 3,715 4,599
Other current assets 71,139 29,684
Total current assets 192,834 61,844
Equipment 185,673 207,083
Total assets 378,507 268,927
Current Liabilities    
Accounts payable 396,836 384,147
Accrued liabilities 8,412 37,966
Due to related parties 333,772 307,650
Notes and advances payable 130,128 951,716
Unearned revenue 11,172
Total liabilities 880,320 1,681,479
STOCKHOLDERS' DEFICIT    
Common stock, $0.001 par value, 300,000,000 shares authorized; 40,244,605 and 31,000,000 shares issued and outstanding at November 30, 2016 and May 31, 2016, respectively 40,245 31,000
Additional paid-in capital 4,048,000 1,734,498
Obligation to issue shares 75,000
Accumulated deficit (4,593,517) (3,254,597)
Accumulated other comprehensive income 3,459 1,547
Total stockholders deficit (501,813) (1,412,552)
Total liabilities and stockholders deficit $ 378,507 $ 268,927
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Nov. 30, 2016
May 31, 2016
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares issued 40,244,605 31,000,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Nov. 30, 2016
Nov. 30, 2015
Nov. 30, 2016
Nov. 30, 2015
Revenue        
Sales $ 336 $ 3,767 $ 5,704 $ 5,649
Cost of goods sold 180 2,897 3,591 4,102
Gross margin 156 870 2,113 1,547
Operating expenses        
Amortization 18,510 2,587 36,521 6,500
Consulting fees 75,607 103,252 150,747 189,710
General and administrative expenses 51,239 52,721 95,463 120,683
Research and development costs 67,173 25,185 140,025 578,724
Stock-based compensation 29,306 290,281 78,203 606,866
Total operating expenses 241,835 474,026 500,959 1,502,483
Other items        
Accretion expense (7,473) (13,730)
Gain on sale of equipment 2,979
Interest (5,596) (6,458) (20,991) (11,085)
Loss on settlement of debt (805,353) (805,353)
Net loss (1,060,101) (479,614) (1,338,920) (1,509,042)
Unrealized foreign exchange translation gain 1,881 469 1,912 2,455
Comprehensive loss $ (1,058,220) $ (479,145) $ (1,337,008) $ (1,506,587)
Net loss per common share, basic and diluted $ (0.03) $ (0.02) $ (0.04) $ (0.05)
Weighted average number of shares outstanding, basic and diluted 36,014,128 31,000,000 33,493,364 31,000,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.6.0.2
Shareholders Equity (Unaudited) - USD ($)
Common Stock
Obligation to Issue Shares
Additional Paid-In Capital
Deficit Accumulated
Accumulated Other Comprehensive Income
Total
Beginning balance, amount at May. 31, 2015 $ 31,000 $ 75,000 $ 324,629 $ (1,115,460) $ 765 $ (684,066)
Beginning balance, in shares at May. 31, 2015 31,000,000          
Stock-based compensation     606,866     606,866
Options issued for technology     496,345     496,345
Options issued for consulting fees     20,364     20,364
Net loss for the period       (1,509,042)   (1,509,042)
Translation to reporting currency         2,455 2,455
Ending balance, amount at Nov. 30, 2015 $ 31,000 75,000 1,448,204 (2,624,502) 3,220 (1,067,078)
Ending balance, in shares at Nov. 30, 2015 31,000,000          
Stock-based compensation     261,294     261,294
Warrants issued for term loan     25,000     25,000
Net loss for the period       (630,095)   (630,095)
Translation to reporting currency         (1,673) (1,673)
Ending balance, amount at May. 31, 2016 $ 31,000 75,000 1,734,498 (3,254,597) 1,547 (1,412,552)
Ending balance, in shares at May. 31, 2016 31,000,000          
Shares issued for cash, amount $ 2,383   355,117     357,500
Shares issued for cash, shares 2,383,333          
Shares issued for debt, amount $ 6,712   1,805,332     1,812,044
Shares issued for debt, shares 6,711,272          
Issuance of shares subscribed, amount $ 150 (75,000) 74,850    
Issuance of shares subscribed, shares 150,000          
Stock-based compensation     78,203     78,203
Net loss for the period       (1,338,920)   (1,338,920)
Translation to reporting currency         1,912 1,912
Ending balance, amount at Nov. 30, 2016 $ 40,245 $ 4,048,000 $ (4,593,517) $ 3,459 $ (501,813)
Ending balance, in shares at Nov. 30, 2016 40,244,605          
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Nov. 30, 2016
Nov. 30, 2015
Cash flows used in operating activities    
Net loss $ (1,338,920) $ (1,509,042)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accretion expense 13,730
Accrued interest on notes payable 20,991 11,085
Amortization 36,521 6,500
Consulting fees - non-cash 20,364
Foreign exchange gain (4,264) (8,190)
Gain on sale of equipment (2,979)
Loss on settlement of debt 805,353
Research and development costs - non-cash 496,345
Stock-based compensation 78,203 606,866
Changes in operating assets and liabilities:    
Inventory 797 (94)
Other current assets (40,213) 8,349
Accounts payable 12,358 81,663
Accrued liabilities (29,553) (21,024)
Unearned revenue 11,471 6,592
Due to related parties 30,221 140,525
Net cash flows used in operating activities (403,305) (163,040)
Cash flows used in investing activities:    
Acquisition of equipment (14,940) (32,838)
Net cash used in investing activities (14,940) (32,838)
Cash flows from financing activities:    
Advances payable 2,684 (45,800)
Proceeds from notes payable 148,754 242,000
Proceeds from subscription to shares 357,500
Net cash provided by financing activities 508,938 196,200
Effects of foreign currency exchange on cash (274) (37)
Increase in cash 90,419 285
Cash, beginning 27,561 1,258
Cash, ending 117,980 1,543
Non-cash investing transactions:    
Sale of equipment recorded as settlement of due to related parties $ 19,301
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 1 - Organization and Nature of Operations
 6 Months Ended
Nov. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Note 1 - Organization and Nature of Operations

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

 

Cell MedX Corp. (the “Company”) was incorporated under the laws of the State of Nevada. On November 26, 2014, the Company formed a subsidiary, Avyonce Cosmedics Inc., (“Avyonce”) and on April 26, 2016, the Company formed an additional subsidiary, Cell MedX (Canada) Corp. (“Cell MedX Canada”). Both subsidiaries were formed under the laws of British Columbia.

 

The Company is an early development stage company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure.

 

Unaudited Interim Financial Statements

The unaudited interim consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”). They do not include all information and footnotes required by GAAP for complete financial statements. Except as disclosed herein, there have been no material changes in the information disclosed in the notes to the consolidated financial statements for the year ended May 31, 2016, included in the Company’s Annual Report on Form 10-K, filed with the SEC. The interim unaudited consolidated financial statements should be read in conjunction with those audited consolidated financial statements included in Form 10-K. In the opinion of management, all adjustments considered necessary for fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three and six month periods ended November 30, 2016, are not necessarily indicative of the results that may be expected for the year ending May 31, 2017.

 

Reclassifications

Certain prior period amounts in the accompanying unaudited consolidated interim financial statements have been reclassified to conform to the current period’s presentation.  These reclassifications had no net effect on the consolidated results of operations or financial position for any period presented.

 

Going Concern

The accompanying unaudited consolidated interim financial statements have been prepared assuming the Company will continue as a going concern. Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet its obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations.  The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern.  These unaudited interim consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.  Management intends to obtain additional funding by borrowing funds from its directors and officers, issuing promissory notes and/or a private placement of common stock.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 2 - Related Party Transactions
 6 Months Ended
Nov. 30, 2016
Related Party Transactions [Abstract]  
Note 2 - Related Party Transactions

NOTE 2– RELATED PARTY TRANSACTIONS

 

Amounts due to related parties, other than notes payable to related parties (Notes 6 and 7) at November 30, 2016, and May 31, 2016:

   

November 30,

2016

    

May 31,

2016

  
Due to the Chief Executive Officer (“CEO”) and President   $ 89,654     $ 66,254  
Due to the Vice President (“VP”), Corporate Strategy     98,220       95,575  
Due to the VP, Technology and Operations     59,958       56,596  
Due to the Chief Medical Officer     81,059       81,059  
Due to a company owned by VP,  Corporate Strategy  and VP Technology and Operations     1,704       1,747  
Due to the Chief Financial Officer (“CFO”)     3,177       6,419  
Due to related parties   $ 333,772     $ 307,650  

Amounts are unsecured, due on demand and bear no interest.

 

During the six months ended November 30, 2016 and 2015, the Company had the following transactions with related parties:

 

   

November 30,

2016

    

November 30,

2015

  
Management fees incurred to the CEO and President   $ 21,600     $ 21,600  
Stock-based compensation  incurred to the CEO and President (Note 8)     11,600       446,942  
Management fees incurred to the CFO     6,000       6,000  
Consulting fees incurred to the VP, Corporate Strategy     25,178       55,669  
Consulting fees incurred to the VP, Technology and Operations     25,178       43,768  
Net payments received  for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy     -       (19,301 )
Value of options  issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8)     -       496,345  
Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs     -       50,000  
Stock-based compensation  incurred to the Chief Medical Officer (Note 8)     66,603       159,924  
Research and development costs incurred to a company  controlled by the Chief Medical Officer     -       25,700  
Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6)     5,549       -  
Accretion expense associated with a term loan entered into with significant shareholder (Note 7)     13,730       -  
Total transactions with related parties   $ 175,438     $ 1,286,647  

 

On September 26, 2016, the Company entered into a letter agreement (the “Letter Agreement”) with Jean Arnett and Brad Hargreaves to cancel the unvested portion of the options granted to Ms. Arnett and Mr. Hargreaves by the Company (Note 8). In addition, the Company renegotiated its consulting arrangements with Ms. Arnett and Mr. Hargreaves. Based on the Letter Agreement, the Company has agreed to pay each of Ms. Arnett and Mr. Hargreaves CAD$5,000 per month, beginning effective August 1, 2016, for duration of six months.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 3 - Equipment
 6 Months Ended
Nov. 30, 2016
Property, Plant and Equipment [Abstract]  
Note 3 - Equipment

NOTE 3 – EQUIPMENT

 

Amortization schedule for the equipment at November 30, 2016, and May 31, 2016:

 

    November 30, 2016     May 31, 2016  
Book value, beginning of the period   $ 207,083     $ 25,846  
Changes during the period     15,111       201,840  
Amortization     (36,521 )     (20,603 )
Book value, end of the period   $ 185,673     $ 207,083  

 

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 4 - Inventory
 6 Months Ended
Nov. 30, 2016
Inventory Disclosure [Abstract]  
Note 4 - Inventory

NOTE 4 – INVENTORY

 

As at November 30, 2016, the inventory consisted of supplies held for resale, and was valued at $3,715 (May 31, 2016 - $4,599). The Company uses lower of cost or net realizable value to determine the book value of the inventory at reporting date.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 5 - Unearned Revenue
 6 Months Ended
Nov. 30, 2016
Notes to Financial Statements  
Note 5 - Unearned Revenue

NOTE 5 – UNEARNED REVENUE

 

On September 14, 2016, the Company received a $11,172 (CAD$15,000) deposit.

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 6 - Notes and Advances Payable
 6 Months Ended
Nov. 30, 2016
Debt Disclosure [Abstract]  
Note 6 - Notes and Advances Payable

NOTE 6 – NOTES AND ADVANCES PAYABLE

 

The tables below summarize the short-term loans and advances outstanding as at November 30, 2016, and May 31, 2016:

 

As at November 30, 2016
Principal Outstanding

Interest Rate

per Annum

  

Accrued

Interest / Accretion

Total Book

Value

$      49,151 6% Non-convertible $         1,031 $        50,182
32,295 6% Related Party (Note 2) 663 32,958
50,000 6% Term Loan- Related Party (Notes 2 and 7) 18,758 43,758
3,230 0% Advances - 3,230
$    134,676     $       20,452 $      130,128

 

 

As at May 31, 2016
Principal Outstanding

Interest Rate

per Annum

  

Accrued

Interest / Accretion

Total Book

Value

      $    195,000 6% Convertible   $        18,588 $       213,588
490,000 6% Non-convertible 12,842 502,842
197,000 6% Related Party (Note 2) 7,620 204,620
50,000 6% Term Loan- Related Party (Notes 2 and 7) 5,028 30,028
638 0% Advances - 638
$    932,638     $       44,078 $      951,716

.

During the six-month period ended November 30, 2016, the Company entered into a number of loan agreements for $75,000 (May 31, 2016 - $480,000). These loans bare interest at 6% per annum, are unsecured and payable on demand. During the same period, the Company entered into a number of loan agreements with Mr. Richard Jeffs (“Mr. Jeffs”), a major shareholder, for a total of $73,754 (CAD$96,500) (May 31, 2016 – $247,000). The loans of CAD$96,500 bear interest at 6% per annum, are unsecured and are payable on demand.

 

On September 30, 2016, Mr. Jeffs notified the Company that he had assigned all rights to his claims against the Company in the amount of $250,000 to two unaffiliated parties. The assignees notified the Company of their intention to convert the debt acquired by them from Mr. Jeffs into the units of the Company’s common stock as part of the non-brokered private placement offering (the “Offering”), which the Company closed on October 12, 2016 (Note 8).

 

On October 12, 2016, as part of its Offering, the Company settled a total of $1,006,691 owed under the notes payable (the “Debt”), which consisted of $949,001 in principal and $57,690 in accrued interest. The Debt was converted to 6,711,272 units of the Company's common stock at $0.15 per unit. Each unit consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year. The Company recorded a loss on settlement of $805,353, which resulted from the difference between the fair market value of the stock at the date of the conversion being $0.27 per share, and price of the unit offered as part of the private placement being $0.15 per unit.

 

As of November 30, 2016, the Company recorded $20,991 (2015 - $11,085) in interest expense associated with above loans.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 7 - Term Loan
 6 Months Ended
Nov. 30, 2016
Notes to Financial Statements  
Note 7 - Term Loan

NOTE 7 – TERM LOAN

 

On March 3, 2016, the Company entered into a loan agreement (the “Term Loan Agreement”) with Mr. Jeffs for a loan in the principal amount of $50,000 maturing March 3, 2017, with interest payable at a rate of 6% per annum (the “Term Loan”).  As additional consideration for the Term Loan, the Company issued to Mr. Jeffs share purchase warrants (the “Warrants”) for the purchase of up to 2,000,000 shares of the Company’s common stock, exercisable for a period of five years at a price of $0.15 per share if exercised during the first year, $0.25 per share if exercised during the second year, $0.40 per share if exercised during the third year, $0.60 per share if exercised during the fourth year and $0.75 per share during the fifth year. The Warrants were determined to be detachable from the debt instrument, as the debt instrument does not have to be surrendered to exercise the warrant. Under the guidance provided by ASC 470-20-25-2, proceeds from the sale of debt instrument with stock purchase warrants must be allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds allocated to the warrants was $25,000 and was recorded to additional paid-in capital.

 

The Term Loan has effective interest rate of 77.51%, which was due primarily to the recording of non-cash accretion interest. During the six-month period ended November 30, 2016, the Company recognized accretion expense of $13,730 (2015 - $Nil).

 

At March 3, 2016, the fair value of Warrants was valued using the Black-Scholes Option pricing model using the following assumptions:

 

  At March 3, 2016
Expected Warrant Life 5 years
Risk-Free Interest Rate 1.33%
Expected Dividend Yield Nil
Expected Stock Price Volatility 16%

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital
 6 Months Ended
Nov. 30, 2016
Equity [Abstract]  
Note 8- Share Capital

NOTE 8 – SHARE CAPITAL

 

In January 2015 the Company received a subscription to 150,000 units (each a “Unit”) at a price of $0.50 per Unit for total proceeds of $75,000. Each Unit consisted of one share of the Company’s common stock and one warrant for the purchase of one additional share of the Company’s common stock, exercisable at a price of $1.00 per share, expiring on December 31, 2015. The Company issued the shares on September 20, 2016. Since the expiration date of the warrants had passed, the warrants were not issued.

 

On October 12, 2016, the Company closed its Offering at a price of $0.15 per unit, by issuing 2,383,333 units for cash proceeds of $357,500 and 6,711,272 units to the holders of the Company’s notes payable (Note 6) for debt settlement of $1,006,691. Each unit sold under the Offering consisted of one common share of the Company and one share purchase warrant expiring on October 12, 2021, and entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.

 

Options

 

On November 25, 2014, as part of the technology purchase agreement dated for reference October 16, 2014, and as amended on October 28, 2014 and November 13, 2014, the Company issued to the vendors of the Technology (the “Vendors”) options for the purchase of up to 20,000,000 shares of the Company’s common stock at an initial exercise price of $0.05 per share and expiring on the 5th year anniversary of the applicable vesting date, or on December 31, 2019, for those options that have not vested.

 

On August 26, 2015, the board of directors of the Company determined that the options to purchase up to 2,500,000 common shares of the Company’s common stock granted to the Vendors for the Technology, which were to vest upon the design and commencement of the first clinical trial, have vested. The total fair value of the vested options was calculated to be $496,345 (Note 2) and was determined using the Black-Scholes Option pricing model at the grant date using the following assumptions:

 

  At August 26, 2015
Expected Life of Options 5 years
Risk-Free Interest Rate 1.49%
Expected Dividend Yield Nil
Expected Stock Price Volatility 216%

 

On September 26, 2016, the Company entered into a letter agreement with the Vendors to cancel remaining 17,500,000 options (Note 2).

 

On January 13, 2015, the Company issued 2,400,000 non-transferrable options to its Chief Medical Officer. The options are exercisable at $0.67 per share and vest quarterly starting on March 31, 2015, in equal portions of 200,000 shares per vesting period, and expire on the 5th year anniversary of the applicable vesting date.

 

The total fair value of the options was calculated to be $591,503 and was determined using the Black-Scholes Option pricing model at the grant date using the following assumptions:

 

  At January 13, 2015
Expected Life of Options 5 years from vesting
Risk-Free Interest Rate 1.37%
Expected Dividend Yield Nil
Expected Stock Price Volatility 27%


As of November 30, 2016, options to acquire up to 1,400,000 shares of the Company’s common stock have vested, and the Company recognized $66,603 (2015 - $159,924) (Note 2) as stock-based compensation expense for the six-month period ended November 30, 2016. Further $58,197 will be recognized in the future periods.

 

On August 5, 2015, the Company issued to its CEO, President and a member of the board of directors options to purchase up to 2,500,000 shares of the Company’s common stock (the “CEO Options”). The CEO Options are exercisable at $0.35 per share. As of November 30, 2016, all CEO Options have vested.

 

The CEO Options expire on the 5th year anniversary of the particular vesting date, subject to certain early termination provisions, upon the death of the optionee, or if the optionee ceases to act for the Company in any capacity either voluntarily or as a result of a termination or removal for cause.

 

The total fair value of the options was calculated to be $616,886 and was determined using the Black-Scholes option pricing model at the grant date using the following assumptions:

 

  At August 5, 2015
Expected Life of Options 5 years from vesting
Risk-Free Interest Rate 1.65%
Expected Dividend Yield Nil
Expected Stock Price Volatility 218%


During the six-month period ended November 30, 2016, the Company recognized $11,600 as share-based compensation expense (2015 - $446,942) (Note 2).

 

The changes in the number of stock options outstanding during the six-month period ended November 30, 2016, and for the year ended May 31, 2016, are as follows:

 

   

Six months ended

November 30, 2016

    

Year ended

May 31, 2016

  
    Number of options     Weighted average exercise price     Number of options     Weighted average exercise price  
Options outstanding, beginning     25,050,000     $ 0.14       22,400,000     $ 0.12  
Options granted     -       n/a       2,650,000     $ 0.34  
Options cancelled     (17,500,000 )   $ 0.05       -       n/a  
Options outstanding, ending     7,550,000     $ 0.35       25,050,000     $ 0.14  
Options exercisable, ending     6,550,000     $ 0.30       5,650,000     $ 0.27  

 

Details of options outstanding and exercisable as at November 30, 2016, are as follows:

 

Exercise price Grant date

Number of options

granted

Number of options

exercisable

$0.05 November 25, 2014 2,500,000 2,500,000
$0.67 January 13, 2015 2,400,000 1,400,000
$0.35 August 5, 2015 2,500,000 2,500,000
$0.20 September 23, 2015 150,000 150,000
    7,550,000 6,550,000


At November 30, 2016, the weighted average remaining contractual life of the stock options outstanding and exercisable was 3.89 years.

 

Warrants

 

On March 3, 2016, the Company issued non-transferrable share purchase warrants to acquire up to 2,000,000 shares of the Company’s common stock expiring on March 3, 2021, to Mr. Jeffs as additional consideration for the Term Loan (Note 7). The exercise price of these warrants is as follows:

 

Period expiring on: Exercise Price
March 3, 2017 $0.15
March 3, 2018 $0.25
March 3, 2019 $0.40
March 3, 2020 $0.60
March 3, 2021 $0.75

 

On October 12, 2016, as part of the Offering, the Company issued warrants to acquire up to 9,094,605 of the Company’s common stock expiring on October 12, 2021. The exercise price of these warrants is as follows:

 

Period expiring on: Exercise Price
October 12, 2017 $0.50
October 12, 2018 $0.75
October 12, 2019 $1.00
October 12, 2020 $1.25
October 12, 2021 $1.50

 

The changes in the number of warrants outstanding during the six-month period ended November 30, 2016, and for the year ended May 31, 2016, are as follows:

 

 

Six months ended

November 30, 2016

Year ended

May 31, 2016

Warrants outstanding, beginning - -
Warrants issued 11,094,605 -
Warrants outstanding, ending 11,094,605 -

 

Details of warrants outstanding as at November 30, 2016, are as follows:

 

Exercise price Expiry Date

Number of warrants

exercisable

$0.15 1st year; $0.25 2nd year; $0.40 3rd year;

$0.60 4th year; $0.75 5th year

 March 3, 2021 2,000,000

$0.50 1st year; $0.75 2nd year; $1.00 3rd year

$1.25 4th year; $1.50 5th year

 October 12, 2021 9,094,605
    11,094,605

 

At November 30, 2016, the weighted average remaining contractual life of the share purchase warrants was 4.76 years.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 9 - Subsequent Events
 6 Months Ended
Nov. 30, 2016
Subsequent Events [Abstract]  
Note 9 - Subsequent Events

NOTE 9 – SUBSEQUENT EVENTS

 

a)   Subsequent to November 30, 2016, the Company received 20 eBalance Pro wellness devices.  The Company paid the developer $93,764 (EURO 86,776) for the devices.  

 

b)   In January 2017 the Company received CAD$40,000 under loan agreements with a non-related party, and CAD$15,000 under a loan agreement with Mr. Richard Jeffs. The loans bear interest at 6% per annum, are unsecured and payable on demand (Note 6).
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 2 - Related Party Transactions (Tables)
 6 Months Ended
Nov. 30, 2016
Related Party Transactions [Abstract]  
Schedule of Amounts Due To Related Parties

   

November 30,

2016

    

May 31,

2016

  
Due to the Chief Executive Officer (“CEO”) and President   $ 89,654     $ 66,254  
Due to the Vice President (“VP”), Corporate Strategy     98,220       95,575  
Due to the VP, Technology and Operations     59,958       56,596  
Due to the Chief Medical Officer     81,059       81,059  
Due to a company owned by VP,  Corporate Strategy  and VP Technology and Operations     1,704       1,747  
Due to the Chief Financial Officer (“CFO”)     3,177       6,419  
Due to related parties   $ 333,772     $ 307,650  
Schedule of Related Party Transactions

   

November 30,

2016

    

November 30,

2015

  
Management fees incurred to the CEO and President   $ 21,600     $ 21,600  
Stock-based compensation  incurred to the CEO and President (Note 8)     11,600       446,942  
Management fees incurred to the CFO     6,000       6,000  
Consulting fees incurred to the VP, Corporate Strategy     25,178       55,669  
Consulting fees incurred to the VP, Technology and Operations     25,178       43,768  
Net payments received  for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy     -       (19,301 )
Value of options  issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8)     -       496,345  
Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs     -       50,000  
Stock-based compensation  incurred to the Chief Medical Officer (Note 8)     66,603       159,924  
Research and development costs incurred to a company  controlled by the Chief Medical Officer     -       25,700  
Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6)     5,549       -  
Accretion expense associated with a term loan entered into with significant shareholder (Note 7)     13,730       -  
Total transactions with related parties   $ 175,438     $ 1,286,647  
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 3 - Equipment (Tables)
 6 Months Ended
Nov. 30, 2016
Property, Plant and Equipment [Abstract]  
Amortization schedule, equipment

 

    November 30, 2016     May 31, 2016  
Book value, beginning of the period   $ 207,083     $ 25,846  
Changes during the period     15,111       201,840  
Amortization     (36,521 )     (20,603 )
Book value, end of the period   $ 185,673     $ 207,083  
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 6 - Notes and Advances Payable (Tables)
 6 Months Ended
Nov. 30, 2016
Debt Disclosure [Abstract]  
Schedule of short term loans and advances, November 30, 2016

As at November 30, 2016
Principal Outstanding

Interest Rate

per Annum

  

Accrued

Interest / Accretion

Total Book

Value

$      49,151 6% Non-convertible $         1,031 $        50,182
32,295 6% Related Party (Note 2) 663 32,958
50,000 6% Term Loan- Related Party (Notes 2 and 7) 18,758 43,758
3,230 0% Advances - 3,230
$    134,676     $       20,452 $      130,128
Schedule of short term loans and advances, May 31, 2016

As at May 31, 2016
Principal Outstanding

Interest Rate

per Annum

  

Accrued

Interest / Accretion

Total Book

Value

      $    195,000 6% Convertible   $        18,588 $       213,588
490,000 6% Non-convertible 12,842 502,842
197,000 6% Related Party (Note 2) 7,620 204,620
50,000 6% Term Loan- Related Party (Notes 2 and 7) 5,028 30,028
638 0% Advances - 638
$    932,638     $       44,078 $      951,716
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 7 - Term Loan (Tables)
 6 Months Ended
Nov. 30, 2016
Notes to Financial Statements  
Assumptions, Fair value of warrants

 

  At March 3, 2016
Expected Warrant Life 5 years
Risk-Free Interest Rate 1.33%
Expected Dividend Yield Nil
Expected Stock Price Volatility 16%
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital (Tables)
 6 Months Ended
Nov. 30, 2016
Equity [Abstract]  
Schedule of Fair Value of Options Granted and Assumptions August 26, 2015
       
    At August 26, 2015  
Expected Life of Options   5 years  
Risk-Free Interest Rate     1.49%  
Expected Dividend Yield   Nil  
Expected Stock Price Volatility     216%  
Schedule of Fair Value of Options Granted and Assumptions January 13, 2015
       
    At January 13, 2015  
Expected Life of Options   5 years from vesting  
Risk-Free Interest Rate       1.37%  
Expected Dividend Yield   Nil   
Expected Stock Price Volatility     27%  
Schedule of Fair Value of Options Granted and Assumptions August 5, 2015
       
   

At August 5,

2015

  
Expected Life of Options   5 years from vesting  
Risk-Free Interest Rate     1.65%   
Expected Dividend Yield   Nil  
Expected Stock Price Volatility     218%  
Schedule of Changes in Stock Options

   

Six months ended

November 30, 2016

    

Year ended

May 31, 2016

  
    Number of options     Weighted average exercise price     Number of options     Weighted average exercise price  
Options outstanding, beginning     25,050,000     $ 0.14       22,400,000     $ 0.12  
Options granted     -       n/a       2,650,000     $ 0.34  
Options cancelled     (17,500,000 )   $ 0.05       -       n/a  
Options outstanding, ending     7,550,000     $ 0.35       25,050,000     $ 0.14  
Options exercisable, ending     6,550,000     $ 0.30       5,650,000     $ 0.27  
Schedule of Outstanding Options

Exercise price Grant date

Number of options

granted

Number of options

exercisable

$0.05 November 25, 2014 2,500,000 2,500,000
$0.67 January 13, 2015 2,400,000 1,400,000
$0.35 August 5, 2015 2,500,000 2,500,000
$0.20 September 23, 2015 150,000 150,000
    7,550,000 6,550,000
Schedule of Warrant expiration dates, March 3, 2016 issuance
Period expiring on: Exercise Price
March 3, 2017 $0.15
March 3, 2018 $0.25
March 3, 2019 $0.40
March 3, 2020 $0.60
March 3, 2021 $0.75
Schedule of Warrant expiration dates, October 12, 2016 issuance
Period expiring on: Exercise Price
October 12, 2017 $0.50
October 12, 2018 $0.75
October 12, 2019 $1.00
October 12, 2020 $1.25
October 12, 2021 $1.50
Schedule of changes in Warrants
 

Six months ended

November 30, 2016

Year ended

May 31, 2016

Warrants outstanding, beginning - -
Warrants issued 11,094,605 -
Warrants outstanding, ending 11,094,605 -
Schedule of Warrants outstanding
Exercise price Expiry Date

Number of warrants

exercisable

$0.15 1st year; $0.25 2nd year; $0.40 3rd year;

$0.60 4th year; $0.75 5th year

 March 3, 2021 2,000,000

$0.50 1st year; $0.75 2nd year; $1.00 3rd year

$1.25 4th year; $1.50 5th year

 October 12, 2021 9,094,605
    11,094,605
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 2 - Related Party Transactions - Schedule of Amounts Due To Related Parties (Details) - USD ($)
Nov. 30, 2016
May 31, 2016
Related Party Transactions [Abstract]    
Due to the Chief Executive Officer (CEO) and President $ 89,654 $ 66,254
Due to the Vice President (VP), Corporate Strategy 98,220 95,575
Due to the VP, Technology and Operations 59,958 56,596
Due to the Chief Medical Officer 81,059 81,059
Due to a company owned by VP, Corporate Strategy and VP Technology and Operations 1,704 1,747
Due to the Chief Financial Officer (CFO) 3,177 6,419
Due to related parties $ 333,772 $ 307,650
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 2 - Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($)
Nov. 30, 2016
Nov. 30, 2015
Related Party Transactions [Abstract]    
Management fees incurred to the CEO and President $ 21,600 $ 21,600
Stock-based compensation incurred to the CEO and President (Note 8) 11,600 446,942
Management fees incurred to the CFO 6,000 6,000
Consulting fees incurred to the VP, Corporate Strategy 25,178 55,669
Consulting fees incurred to the VP, Technology and Operations 25,178 43,768
Net payments received for equipment sold to the VP, Technology and Operations and VP, Corporate Strategy (19,301)
Value of options issued and vested for Technology acquired from the VP, Technology and Operations and VP, Corporate Strategy, and recorded as part of research and development costs (Note 8) 496,345
Consulting fees incurred to the Chief Medical Officer recorded as part of research and development costs 50,000
Stock-based compensation incurred to the Chief Medical Officer (Note 8) 66,603 159,924
Research and development costs incurred to a company controlled by the Chief Medical Officer 25,700
Accrued interest expense incurred to a significant shareholder, included in general and administrative expense (Note 6) 5,549
Accretion expense associated with a term loan entered into with significant shareholder (Note 7) 13,730
Total transactions with related parties $ 175,438 $ 1,286,647
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 2 - Related Party Transactions (Details Narrative)
Sep. 26, 2016
USD ($)
Transactions with Jean Arnett and Brad Hargreaves  
Monthly consulting fee, Canadian Dollars $ 5,000
Term of renegotiated consulting fee commencing August 1, 2016, in months 6
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 3 - Equipment - Amortization schedule, equipment (Details) - USD ($)
Nov. 30, 2016
May 31, 2016
Property, Plant and Equipment [Abstract]    
Book value, beginning of the period $ 207,083 $ 25,846
Changes during the period 15,111 201,840
Amortization 36,521 20,603
Book value, end of the period $ 185,673 $ 207,083
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 4 - Inventory (Details Narrative) - USD ($)
Nov. 30, 2016
May 31, 2016
Inventory Disclosure [Abstract]    
Inventory, supplies for resale $ 3,715 $ 4,599
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 5 - Unearned Revenue (Details Narrative)
Sep. 14, 2016
USD ($)
Notes to Financial Statements  
Deposit received $ 11,172
Deposit received (CDN dollar equivalent) $ 15,000
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, November 30, 2016 (Details)
 6 Months Ended
Nov. 30, 2016
USD ($)
Short Term Borrowing 2  
Principal Outstanding $ 49,151
Interest Rate per Annum 6.00%
Additional Description Non-Convertible
Accrued Interest $ 1,031
Total 50,182
Short Term Borrowing 3  
Principal Outstanding $ 32,295
Interest Rate per Annum 6.00%
Additional Description Related Party(Note 2)
Accrued Interest $ 663
Total 32,958
Short Term Borrowing 4  
Principal Outstanding $ 50,000
Interest Rate per Annum 6.00%
Additional Description Term Loan - Related Party (Notes 2 and 7)
Accrued Interest $ 18,758
Total 43,758
Short Term Borrowing 5  
Principal Outstanding $ 3,230
Interest Rate per Annum 0.00%
Additional Description Advances
Accrued Interest
Total 3,230
Short Term Borrowing Total  
Principal Outstanding 134,676
Accrued Interest 20,452
Total $ 130,128
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, May 31, 2016 (Details)
 12 Months Ended
May 31, 2016
USD ($)
Short term borrowing 1  
As at May 31, 2016  
Principal Outstanding $ 195,000
Interest Rate per Annum 6.00%
Additional Description Convertible
Accrued Interest $ 18,588
Total 213,588
Short term borrowing 2  
As at May 31, 2016  
Principal Outstanding $ 490,000
Interest Rate per Annum 6.00%
Additional Description Non-Convertible
Accrued Interest $ 12,842
Total 502,842
Short term borrowing 3  
As at May 31, 2016  
Principal Outstanding $ 197,000
Interest Rate per Annum 6.00%
Additional Description Related party(Note 2)
Accrued Interest $ 7,620
Total 204,620
Short Term Borrowing 4  
As at May 31, 2016  
Principal Outstanding $ 50,000
Interest Rate per Annum 6.00%
Additional Description Related Party Term Loan (Notes 2 and 7)
Accrued Interest $ 5,028
Total 30,028
Short Term Borrowing 5  
As at May 31, 2016  
Principal Outstanding $ 638
Interest Rate per Annum 0.00%
Additional Description Advances
Accrued Interest
Total 638
Short Term Borrowing Total  
As at May 31, 2016  
Principal Outstanding 932,638
Accrued Interest 44,078
Total $ 951,716
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 6 - Notes and Advances Payable (Details Narrative) - USD ($)
 6 Months Ended
Nov. 30, 2016
Nov. 30, 2015
Oct. 12, 2021
Oct. 12, 2020
Oct. 12, 2019
Oct. 12, 2018
Oct. 12, 2017
Oct. 12, 2016
Sep. 30, 2016
Notes and advances                  
Loans, unrelated parties $ 75,000 $ 480,000              
Interest rate 6.00% 6.00%              
Loans, Richard Jeffs, major shareholder, total (USD) $ 73,754 $ 247,000              
Loans, Richard Jeffs, major shareholder, total (CAD) 96,500                
Loans, Richard Jeffs, due on demand, (CAD) $ 96,500                
Interest rate 6.00%                
Interest expense $ 20,991 $ 11,085              
Transactions with Richard Jeffs                  
Amount of assignment of debt to third parties                 $ 250,000
Non-brokered Private Placement Offering and debt settlement                  
Price Per Unit               $ 0.15  
Units Issued to Holders of Notes payable               6,711,272  
Debt Settlement proceeds               $ 1,006,691  
Principal converted to shares               949,001  
Accrued interest converted to shares               57,690  
Terms of Units Each unit consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.                
Exercise Price, Share purchase warrants     $ 1.5 $ 1.25 $ 1 $ .75 $ .5    
Loss on debt settlement               $ 805,353  
Fair market value of common stock on date of debt conversion               $ 0.27  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 7 - Term Loan - Assumptions, Fair value of warrants (Details)
 6 Months Ended
Nov. 30, 2016
Mar. 03, 2016
Assumptions used in warrant valuation    
Expected Warrant Life 5 years  
Risk-Free Interest Rate   1.33%
Expected Dividend Yield  
Expected Stock Price Volatility   16.00%
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 7 - Term Loan (Details Narrative) - USD ($)
 6 Months Ended
Nov. 30, 2016
Nov. 30, 2015
Mar. 03, 2021
Mar. 03, 2020
Mar. 03, 2019
Mar. 03, 2018
Mar. 03, 2017
Notes to Financial Statements              
Loan proceeds $ 50,000            
Interest rate 6.00%            
Share purchase warrants issued as consideration 2,000,000            
Term of warrants, years 5            
Exercise price, warrants     $ .75 $ .60 $ .40 $ .25 $ .15
Effective interest rate 7751.00%            
Accretion Expense $ 13,730          
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 26, 2015 (Details)
 6 Months Ended
Nov. 30, 2016
Aug. 26, 2015
Option Valuation Assumptions    
Expected Life of Options 5 years  
Risk-Free Interest Rate   1.49%
Expected Dividend Yield  
Expected Stock Price Volatility   216.00%
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions January 13, 2015 (Details)
 6 Months Ended
Nov. 30, 2016
Jan. 13, 2015
Option Valuation Assumptions    
Expected Life of Options 5 years  
Risk-Free Interest Rate   1.37%
Expected Dividend Yield  
Expected Stock Price Volatility   27.00%
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 5, 2015 (Details)
 6 Months Ended
Nov. 30, 2016
Aug. 05, 2015
Option Valuation Assumptions    
Expected Life of Options 5 years  
Risk-Free Interest Rate   1.65%
Expected Dividend Yield  
Expected Stock Price Volatility   218.00%
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Changes in Stock Options (Details) - $ / shares
 6 Months Ended 12 Months Ended
Nov. 30, 2016
May 31, 2016
Stock Option Activity    
Options outstanding, beginning   22,400,000
Options granted 2,650,000
Options cancelled 17,500,000
Options outstanding, ending 7,550,000  
Options exercisable, ending 6,550,000  
Weighted Average Exercise Price    
Options outstanding, beginning $ .14 $ .12
Options granted .34
Options cancelled 0.05
Options outstanding, ending .35 .14
Options exercisable, ending $ .30 $ .27
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Outstanding Options (Details) - $ / shares
Nov. 30, 2016
Sep. 23, 2015
Aug. 05, 2015
May 31, 2015
Jan. 13, 2015
Nov. 25, 2014
Details of Options Outstanding            
Exercise Price   $ 0.20 $ 0.35   $ 0.67 $ 0.05
Number of Options Granted   150,000 2,500,000   2,400,000 2,500,000
Number of Options Exercisable 6,550,000 150,000 2,500,000   1,400,000 2,500,000
Total Options granted 7,550,000     22,400,000    
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Warrant Exercise Prices March 2016 (Details) - $ / shares
Mar. 03, 2021
Mar. 03, 2020
Mar. 03, 2019
Mar. 03, 2018
Mar. 03, 2017
Equity [Abstract]          
Exercise price, warrants $ .75 $ .60 $ .40 $ .25 $ .15
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Warrant Exercise Prices October 2016 (Details) - $ / shares
Oct. 12, 2021
Oct. 12, 2020
Oct. 12, 2019
Oct. 12, 2018
Oct. 12, 2017
Equity [Abstract]          
Exercise price, warrants $ 1.5 $ 1.25 $ 1 $ .75 $ .5
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Changes in Warrants (Details) - shares
 6 Months Ended 12 Months Ended
Nov. 30, 2016
May 31, 2016
Warrant Activity    
Warrants outstanding, beginning
Warrants issued 11,094,605
Warrants outstanding, ending 11,094,605
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital - Schedule of Warrants Outstanding (Details) - shares
 6 Months Ended 60 Months Ended
Nov. 30, 2016
Oct. 12, 2021
Mar. 03, 2021
Details of Warrants Oustanding      
Number of warrants exerciseable 11,094,605    
Terms of Warrant      
Details of Warrants Oustanding      
Exercise Price     $0.15 1st year; $0.25 2nd year; $0.40 3rd year; $0.60 4th year; $0.75 5th year
Number of warrants exerciseable     2,000,000
Warrant expiry date     Mar. 03, 2021
Terms of Warrant      
Details of Warrants Oustanding      
Exercise Price   $0.50 1st year; $0.75 2nd year; $1.00 3rd year; $1.25 4th year; $1.50 5th year  
Number of warrants exerciseable   9,094,605  
Warrant expiry date   Oct. 12, 2021  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 8 - Share Capital (Details Narrative) - USD ($)
 6 Months Ended 12 Months Ended
Nov. 30, 2016
Nov. 30, 2015
May 31, 2015
Oct. 12, 2021
Oct. 12, 2020
Oct. 12, 2019
Oct. 12, 2018
Oct. 12, 2017
Oct. 12, 2016
Sep. 26, 2016
Mar. 03, 2016
Aug. 26, 2015
Aug. 05, 2015
Jan. 13, 2015
Nov. 25, 2014
Equity [Abstract]                              
Subscription units     150,000                        
Price per Unit     $ 0.50                        
Proceeds from subscription     $ 75,000                        
Terms of Units Each Unit consists of one share of the Company's common stock and one warrant for the purchase of one additional share of the Company's common stock, exercisable at a price of $1.00 per share, expiring one year after the issuance of the Units.                            
Non-brokered Private Placement Offering and debt settlement                              
Price Per Unit                 $ 0.15            
Units Issued                 2,383,333            
Total Proceeds                 $ 357,500            
Units Issued to Holders of Notes payable                 6,711,272            
Debt Settlement proceeds                 $ 1,006,691            
Terms of Units Each unit consisted of one common share of the Company and one share purchase warrant entitling the holder to purchase one additional common share for a period of five years after closing at an exercise price of $0.50 per share if exercised during the first year, $0.75 per share if exercised during the second year, $1.00 per share if exercised during the third year, $1.25 per share if exercised during the fourth year, and at $1.50 per share if exercised during the fifth year.                            
Exercise Price, Share purchase warrants       $ 1.5 $ 1.25 $ 1 $ .75 $ .5              
Options Issued - November 25, 2014                              
Stock option issued                             20,000,000
Exercise Price per Share                             $ 0.05
Options Vested                       2,500,000      
Total Fair Value Option Vested                       $ 496,345      
Unvested stock options canceled                   17,500,000          
Options Issued - January 13, 2015 - CMO                              
Stock Option Issued                           2,400,000  
Exercise Price per Share                           $ 0.67  
Share which vest each quarter                           200,000  
Total fair value options granted                           $ 591,503  
Options Vested at report date 1,400,000                            
Stock based compensation expense recognized in period $ 66,603 $ 159,924                          
Stock based compensation expense recognized in future periods 58,197                            
Options Issued August 5, 2015 - CEO                              
Stock Option Issued                         2,500,000    
Exercise Price per Share                         $ .35    
Total fair value options granted                         $ 616,886    
Stock based compensation expense recognized in period $ 11,600 $ 446,942                          
Weighted average remaining contractual life, oustanding stock options at report date 3 years 10 months                            
Warrants                              
Share purchase warrants granted                 9,094,605   2,000,000        
Remaining contractual life 4 years 9 months                            
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.6.0.2
Note 9 - Subsequent Events (Details Narrative)
 1 Months Ended 6 Months Ended
Jan. 31, 2017
USD ($)
Nov. 30, 2016
USD ($)
Subsequent Events [Abstract]    
Number of eBalance Pro wellness devices received   20
Payment to developer for devices   $ 93,764
Payment to developer for devices, EUROS   $ 86,776
Proceeds from Loan Agreements, CAD, unrelated party $ 40,000  
Proceeds from Loan Agreement, CAD, Jeffs $ 15,000  
Interest rate on loans 6.00%  
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.6.0.2 html 77 233 1 false 18 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://CMXC/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://CMXC/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://CMXC/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://CMXC/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Shareholders Equity (Unaudited) Sheet http://CMXC/role/ShareholdersEquity Shareholders Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://CMXC/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Note 1 - Organization and Nature of Operations Sheet http://CMXC/role/Note1-OrganizationAndNatureOfOperations Note 1 - Organization and Nature of Operations Notes 7 false false R8.htm 00000008 - Disclosure - Note 2 - Related Party Transactions Sheet http://CMXC/role/Note2-RelatedPartyTransactions Note 2 - Related Party Transactions Notes 8 false false R9.htm 00000009 - Disclosure - Note 3 - Equipment Sheet http://CMXC/role/Note3-Equipment Note 3 - Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Note 4 - Inventory Sheet http://CMXC/role/Note4-Inventory Note 4 - Inventory Notes 10 false false R11.htm 00000011 - Disclosure - Note 5 - Unearned Revenue Sheet http://CMXC/role/Note5-UnearnedRevenue Note 5 - Unearned Revenue Notes 11 false false R12.htm 00000012 - Disclosure - Note 6 - Notes and Advances Payable Notes http://CMXC/role/Note6-NotesAndAdvancesPayable Note 6 - Notes and Advances Payable Notes 12 false false R13.htm 00000013 - Disclosure - Note 7 - Term Loan Sheet http://CMXC/role/Note7-TermLoan Note 7 - Term Loan Notes 13 false false R14.htm 00000014 - Disclosure - Note 8 - Share Capital Sheet http://CMXC/role/Note8-ShareCapital Note 8 - Share Capital Notes 14 false false R15.htm 00000015 - Disclosure - Note 9 - Subsequent Events Sheet http://CMXC/role/Note9-SubsequentEvents Note 9 - Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Note 2 - Related Party Transactions (Tables) Sheet http://CMXC/role/Note2-RelatedPartyTransactionsTables Note 2 - Related Party Transactions (Tables) Tables http://CMXC/role/Note2-RelatedPartyTransactions 16 false false R17.htm 00000017 - Disclosure - Note 3 - Equipment (Tables) Sheet http://CMXC/role/Note3-EquipmentTables Note 3 - Equipment (Tables) Tables http://CMXC/role/Note3-Equipment 17 false false R18.htm 00000018 - Disclosure - Note 6 - Notes and Advances Payable (Tables) Notes http://CMXC/role/Note6-NotesAndAdvancesPayableTables Note 6 - Notes and Advances Payable (Tables) Tables http://CMXC/role/Note6-NotesAndAdvancesPayable 18 false false R19.htm 00000019 - Disclosure - Note 7 - Term Loan (Tables) Sheet http://CMXC/role/Note7-TermLoanTables Note 7 - Term Loan (Tables) Tables http://CMXC/role/Note7-TermLoan 19 false false R20.htm 00000020 - Disclosure - Note 8 - Share Capital (Tables) Sheet http://CMXC/role/Note8-ShareCapitalTables Note 8 - Share Capital (Tables) Tables http://CMXC/role/Note8-ShareCapital 20 false false R21.htm 00000021 - Disclosure - Note 2 - Related Party Transactions - Schedule of Amounts Due To Related Parties (Details) Sheet http://CMXC/role/Note2-RelatedPartyTransactions-ScheduleOfAmountsDueToRelatedPartiesDetails Note 2 - Related Party Transactions - Schedule of Amounts Due To Related Parties (Details) Details 21 false false R22.htm 00000022 - Disclosure - Note 2 - Related Party Transactions - Schedule of Related Party Transactions (Details) Sheet http://CMXC/role/Note2-RelatedPartyTransactions-ScheduleOfRelatedPartyTransactionsDetails Note 2 - Related Party Transactions - Schedule of Related Party Transactions (Details) Details 22 false false R23.htm 00000023 - Disclosure - Note 2 - Related Party Transactions (Details Narrative) Sheet http://CMXC/role/Note2-RelatedPartyTransactionsDetailsNarrative Note 2 - Related Party Transactions (Details Narrative) Details http://CMXC/role/Note2-RelatedPartyTransactionsTables 23 false false R24.htm 00000024 - Disclosure - Note 3 - Equipment - Amortization schedule, equipment (Details) Sheet http://CMXC/role/Note3-Equipment-AmortizationScheduleEquipmentDetails Note 3 - Equipment - Amortization schedule, equipment (Details) Details 24 false false R25.htm 00000025 - Disclosure - Note 4 - Inventory (Details Narrative) Sheet http://CMXC/role/Note4-InventoryDetailsNarrative Note 4 - Inventory (Details Narrative) Details http://CMXC/role/Note4-Inventory 25 false false R26.htm 00000026 - Disclosure - Note 5 - Unearned Revenue (Details Narrative) Sheet http://CMXC/role/Note5-UnearnedRevenueDetailsNarrative Note 5 - Unearned Revenue (Details Narrative) Details http://CMXC/role/Note5-UnearnedRevenue 26 false false R27.htm 00000027 - Disclosure - Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, November 30, 2016 (Details) Notes http://CMXC/role/Note6-NotesAndAdvancesPayable-ScheduleOfShortTermLoansAndAdvancesNovember302016Details Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, November 30, 2016 (Details) Details 27 false false R28.htm 00000028 - Disclosure - Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, May 31, 2016 (Details) Notes http://CMXC/role/Note6-NotesAndAdvancesPayable-ScheduleOfShortTermLoansAndAdvancesMay312016Details Note 6 - Notes and Advances Payable - Schedule of short term loans and advances, May 31, 2016 (Details) Details 28 false false R29.htm 00000029 - Disclosure - Note 6 - Notes and Advances Payable (Details Narrative) Notes http://CMXC/role/Note6-NotesAndAdvancesPayableDetailsNarrative Note 6 - Notes and Advances Payable (Details Narrative) Details http://CMXC/role/Note6-NotesAndAdvancesPayableTables 29 false false R30.htm 00000030 - Disclosure - Note 7 - Term Loan - Assumptions, Fair value of warrants (Details) Sheet http://CMXC/role/Note7-TermLoan-AssumptionsFairValueOfWarrantsDetails Note 7 - Term Loan - Assumptions, Fair value of warrants (Details) Details 30 false false R31.htm 00000031 - Disclosure - Note 7 - Term Loan (Details Narrative) Sheet http://CMXC/role/Note7-TermLoanDetailsNarrative Note 7 - Term Loan (Details Narrative) Details http://CMXC/role/Note7-TermLoanTables 31 false false R32.htm 00000032 - Disclosure - Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 26, 2015 (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfFairValueOfOptionsGrantedAndAssumptionsAugust262015Details Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 26, 2015 (Details) Details 32 false false R33.htm 00000033 - Disclosure - Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions January 13, 2015 (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfFairValueOfOptionsGrantedAndAssumptionsJanuary132015Details Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions January 13, 2015 (Details) Details 33 false false R34.htm 00000034 - Disclosure - Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 5, 2015 (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfFairValueOfOptionsGrantedAndAssumptionsAugust52015Details Note 8 - Share Capital - Schedule of Fair Value of Options Granted and Assumptions August 5, 2015 (Details) Details 34 false false R35.htm 00000035 - Disclosure - Note 8 - Share Capital - Schedule of Changes in Stock Options (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfChangesInStockOptionsDetails Note 8 - Share Capital - Schedule of Changes in Stock Options (Details) Details 35 false false R36.htm 00000036 - Disclosure - Note 8 - Share Capital - Schedule of Outstanding Options (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfOutstandingOptionsDetails Note 8 - Share Capital - Schedule of Outstanding Options (Details) Details 36 false false R37.htm 00000037 - Disclosure - Note 8 - Share Capital - Schedule of Warrant Exercise Prices March 2016 (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfWarrantExercisePricesMarch2016Details Note 8 - Share Capital - Schedule of Warrant Exercise Prices March 2016 (Details) Details 37 false false R38.htm 00000038 - Disclosure - Note 8 - Share Capital - Schedule of Warrant Exercise Prices October 2016 (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfWarrantExercisePricesOctober2016Details Note 8 - Share Capital - Schedule of Warrant Exercise Prices October 2016 (Details) Details 38 false false R39.htm 00000039 - Disclosure - Note 8 - Share Capital - Schedule of Changes in Warrants (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfChangesInWarrantsDetails Note 8 - Share Capital - Schedule of Changes in Warrants (Details) Details 39 false false R40.htm 00000040 - Disclosure - Note 8 - Share Capital - Schedule of Warrants Outstanding (Details) Sheet http://CMXC/role/Note8-ShareCapital-ScheduleOfWarrantsOutstandingDetails Note 8 - Share Capital - Schedule of Warrants Outstanding (Details) Details 40 false false R41.htm 00000041 - Disclosure - Note 8 - Share Capital (Details Narrative) Sheet http://CMXC/role/Note8-ShareCapitalDetailsNarrative Note 8 - Share Capital (Details Narrative) Details http://CMXC/role/Note8-ShareCapitalTables 41 false false R42.htm 00000042 - Disclosure - Note 9 - Subsequent Events (Details Narrative) Sheet http://CMXC/role/Note9-SubsequentEventsDetailsNarrative Note 9 - Subsequent Events (Details Narrative) Details http://CMXC/role/Note9-SubsequentEvents 42 false false All Reports Book All Reports cmxc-20161130.xml cmxc-20161130.xsd cmxc-20161130_cal.xml cmxc-20161130_def.xml cmxc-20161130_lab.xml cmxc-20161130_pre.xml true true ZIP 60 0001594062-17-000003-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001594062-17-000003-xbrl.zip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end